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CHAPTERl 
INTRODUCTION 
1.1. General characteristics of basal cell carcinoma 
Basal cell carcinoma (BCC) is the most common cutaneous cancer of 
epithelial origin in caucasians (1-3). The tumor was frrst described in 1827 by A. 
Jacob and named as Jacob's ulcer (4). In 1902, E. Krompecher clearly 
delineated this tumor from other epithelial tumors (5). Many synonyms have 
been used for this tumor, e.g. Krompecher's tumor, rodent ulcer, adnexal 
carcinoma, cardnoid of the skin, basalioma, basal cell epithelioma, 
Basalzellenkrebs, non-cornifying epithelioma and basal cell carcinoma. 
Although BCC are slowly growing tumors, a proportion of these tumors 
depending on their specific clinical and histological features are aggressive in 
their biological behaviour leading to mutilation and recurrence after therapy (6-
8). The occurrence of metastasis is extremely seldom, but has been reported 
(9,10). Most metastases were located in the regional lymph nodes. If metastasis 
occurs in the lungs, bones or other internal organs, the prognosis is poor and 
the average survival time is less than 1 year (11). Since these tumors have the 
potential for metastasizing and local destruction, they must be considered as 
cancerous. Therefore, in this thesis they are referred to as basal cell carcinoma. 
One of the most important etiological factors in the development of 
epithelial skin cancer, i.e. basal cell carcinomas and squamous cell carcinomas 
(SCC) is the intensity and duration of skin exposure to the ultraviolet (UV) 
fraction of sun light (1). Areas of the body that are exposed to sun light are 
more prone to develop BCC and SCC than non-exposed areas (1,7). In the case 
of BCC, about 90% are located in the head and neck region, with a particular 
predilection for the upper central part of the face (1,2). However, the superfi-
dal type BCC occurs mainly on the trunk. BCC can also occur on the limbs, but 
seldom on handpalms or footsoles (2,12). The inddence of epithelial skin 
cancer in fair skinned individuals is much higher than in dark skinned 
individuals (2). This observation is highly suggestive for the role of melanin 
pigment as a protector against the UV-fraction of sun light. This is illustrated by 
the observations in albinos of black race in whom the inddence of BCC is 
higher than in normally pigmented black individuals (13-15). The susceptibility 
of fair skinned individuals for developing epithelial skin cancers is also related 
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to their tanning ability. Individuals who sun-bum easily and never tan run a 
higher risk of developing epithelial skin cancers than individuals who tan 
easily. In this respect an increase in the incidence of epithelial skin cancer is 
expected due to several factors. These factors are attributed to the economical 
wellbeing in the western countries which allows individuals to visit sun-
drenched areas of the world more frequently, thereby increasing their exposure 
to the UV-fraction of sun light. A rapidly diminishing protective ozone layer 
around the globe due to chloro-fluoro carbons would also indirectly contribute 
towards an increase in the incidence of epithelial skin cancers in the future. In 
the USA, each year 500.000 new cases of non-melanoma skin cancers are 
diagnosed, which represent 50% of all types of cancer in the USA (16). The 
incidence rate of non-melanoma skin cancer for white Americans in the 
Southern States of the USA is more than 230/100.000 per year and is about 4 
times higher than in the Northern States (17,18). In the central Victoria province 
of Australia, the incidence rate for non-melanoma skin cancer is even higher -
700/100.000 per year (19). Different ratios of BCC and SCC have been reported 
depending on the region and population studied; 10:1 (3) 6.5:1 (20) and 1.3:1 
(21). Little is known about the exact incidence of BCC and SCC in the 
Netherlands. It has been reported at an estimate of 15.000 new cases per year 
(22). At the Academic Hospital Dijkzigt in Rotterdam between 1980 and 1987 
some 800 new cases of non-melanoma skin cancer were diagnosed. The ratio 
of BCC to SCC was 6:1. 
The role of the UV-fraction of sun light as an etiological factor is further 
illustrated by the frequent occurrence of skin cancer in xeroderma pig-
mentosum, a disorder in which the skin is extremely vulnerable to damage from 
UV-radiation due to defects in the DNA-repair mechanisms (23). However, there 
are still some discordent notes on the importance of exposure to UV-radiation 
as being the single most important causative factor in BCC. 
Although, the dorsal side of the hands and the forearms are frequently 
exposed to sun light, the occurrence of BCC in these areas is relatively 
infrequent (1). Almost all sec occur in skin areas which are prominently 
exposed to sun light while two third of the total BCC are observed in these 
areas (1,24). Furthermore, solar dosimetry studies of the face did not show a 
clear correlation between BCC density in a given area and the UV-dose (25). 
Therefore, there must be additional etiological factors which play a role in the 
development of BCC. These factors include injury to the skin by X-rays, chronic 
inflammation, congenital malformations, e.g. nevus sebaceous and exposure to 
inorganic arsenic (1,2,7). Genetic disorders such as the basal cell nevus 
syndrome and the Bazex syndrome are characterized by the development of 
multiple BCC, which may already occur in childhood (26). Recently, it has been 
shown that some BCC and SCC have a point mutation in the r~-oncogenes. 
This indicates that activation of ras-oncogenes may be involved in the develop-
ment of epithelial skin cancer (27). The immune competence of the patient 
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seems to play a role in preventing the development of BCC and SCC (28). The 
inddence and the aggressiveness of epithelial skin cancer are increased in 
organ transplantation patients who receive azathioprine and prednisolone or 
ciclosporin-A as a maintenance anti-graft rejection therapy (29,30). However, in 
these chronically immunocompromised patients the ratio of BCC to SCC reverts 
in favour of sec. It has also been observed that epithelial skin cancers which 
developed in patients with chronic lymphocytic leukemia or lymphoma were 
more aggressive in their behaviour than usual, which may be related to 
defective cell-mediated immunity in these patients (31). 
The clinical forms of BCC are extremely variable (2,3,32). The clinical and 
histological subtypes of BCC are summarized in Table I. 
The early tumors are generally small, pearl-like, raised and rounded areas 
covered by thin epidermis through which a few teleangiectatic vessels are 
visible. Other forms include small lichenoid papules, small erythematous 
plaques, superficial ulcerative papules or keratotic slightly indurated areas. The 
more advanced tumors resemble the same variety of forms as the early lesions. 
One of the most common types, the nodular form which is covered by a 
thinned epidermis will periodically erode and crust and finally result in 
permanent ulceration. In the literature, the ulcerative BCC is referred to as ulcus 
rodent and the large ulcerative BCC as ulcus terebrans (2,12,32). Irregularly 
Table I. Clinical and histological subclassification of basal cell carcinoma. 
Clinical type 
Nodular 
pigmented 
ulcus rodens 
Ulcerative 
ulcus terebrans 
Cicatrizing 
Morphoiec 
Superficial 
Fibroepithelioma 
Histological type 
Non-differentiated -solid 
-pigmented 
Differentiated -adenoid 
-cystic 
-keratotic 
-basosquamous 
Morphoiec 
Superficial 
Fibroepithelioma 
Growth pattern 
Non-infiltrative (Nodular) 
Multifocal 
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distributed melanin pigment may also be present in some BCC. These 
pigmented BCC are sometimes clinically difficult to distinguish from a 
melanoma maligne. The morphoiec type BCC or sclerodermiform BCC is rather 
uncommon and resembles a localized scleroderma. In these tumors a dense 
stromal fibrosis causes a thickened dermal plaque. The margin of the lesion 
cannot be defined visually but only by palpation (2). Further clinical types are 
the dcatrizing type which is characterized by a superfidal nodular plaque 
accompanied by clinically apparent central healing- but histologically evident 
persistent tumor. The superfidal type BCC is characterized by a superfidal 
centrifugal growth pattern with a slightly raised margin and a central zone 
which is covered by scales and crustae. An exceptional type of BCC is the 
premalignant fibro-epithelial tumor (of Pinkus) which is characterized by a 
dome-shaped or pendiculated flesh coloured nodule, mainly located in sacral 
region of the back. The histology is very typical but has the characteristics 
similar to those of BCC (33). 
The broad clinical forms of BCC are also reflected in a variety of histological 
features (34-36). An obvious relationship between the clinical and the 
histological features of BCC has been reported (12). Histologically, the most 
common type of BCC is the undifferentiated solid type (35).The tumor consists 
of individual nests of tumor cells which are surrounded by fibrous stroma. The 
tumor cells resemble epidermal basal cells but they differ in cell size and shape 
and have a large nucleus to cytoplasm ratio. The peripheral cell layer of the 
tumor nests shows a palisade arrangement, whereas the tumor cells inside lie in 
a haphazard fashion. The BCC showing differentiation towards sebaceous 
structures is called cystic, that with eccrine or apocrine differentiation is called 
adenoid and that with keratinization is called keratotic. A special form is the 
basosquamous type which shows characteristics of both BCC and SCC. 
As far as the origin of BCC is concerned, it is still not clear whether they are 
derived from skin adnexal organs or from transformed basal cells of the 
interfollicular epidermis. The observation that histologically, BCC show patterns 
of differentiation similar to different structures of skin adnexal organs argue for 
an adnexal origin (34,35). In addition, Kint observed a similarity between hair-
cycle growth and BCC (12). However, in many BCC, especially the superficial 
type BCC, tumor buds show no contact with skin adnexal organs, but are only 
observed in close contact with the basal cell layer of the epidermis. This 
observation supports an interfollicular epithelial origin of BCC. Considering 
these observations it has been suggested that the tumor cells of BCC may arise 
from undifferentiated epithelial cells that can originate from any point of the 
epidermis or adnexal organ (12,33). 
The mode of growth of a BCC is an important criterium to predict whether it 
will behave aggressively (6,8,37). The growth patterns of BCC can be classified 
as the nodular type which is characterized by well-circumscribed nodules with 
smooth and sharply demarcated border; the infiltrative type which is 
4 
Introduction 
characterized by poorly circumscribed tumor nests with irregular edges and 
often elongated with spikey processes reaching deep into the dermis or even 
into the subcutis; and the multi-focal type which is characterized by multifocal 
tumor buds arising from the overlaying epidermis and it mostly exhibits a 
superficial expansion growth. The infiltrative growth pattern is an important 
feature for its aggressive behaviour which is reflected in a high recurrence rate 
after treatment (8,37). 
The aggressiveness of BCC has also been correlated with the site of its origin. 
The location of BCC in the embryological fusion planes show a tendency to 
invade into the depth (38). Areas with a high recurrence rate are the midface, 
especially the medial canthus, nasolabial fold and the nosetip, and the 
postauricular region (38-40). The high recurrence rate of the BCC in these 
particular areas may not only be due to its growth pattern along the 
embryological fusion planes, but also on the delay prior to clinical detection 
and the mode of therapy that is used (7). The current treatment methods 
include excision, cryosurgery, irradiation and currettage and electrodessication. 
1.2. Tumor markers 
Products or constituents of tumor cells which differ in antigenicity, distribu-
tion or quantity from normal tissue cells can be considered as tumor markers. 
These markers include carcinoembryonic antigens (CEA), alpha-fetoprotein 
(AFP), tumor-type associated antigens, mucinous carcinoma-associated antigens 
and intermediate-sized filaments (cytokeratins). The importance and the value 
of tumor markers in clinical oncology may be summarized as follows. a. The 
detection of tumor markers in a patient's serum may be helpful in an early 
diagnosis. b. The diagnosis and the classification of tumor tissue of unknown or 
disputable origin. c. The localisation and the staging of metastases is possible 
using radiolabeled specific monoclonal antibodies (MoAb) against tumor 
markers. d. Specific monoclonal antibodies raised against tumor markers can be 
used for targeting chemotherapeutic agents. One group of tumor markers called 
tumor associated antigens (TAA) are glycoproteins or glycolipids in nature and 
are mainly present on the surface of tumor cells. TAA represent a wide 
spectrum of antigens which may evoke anti-tumor immune response which can 
be assessed using a variety of immunological assays (41,42). 
To date, tumor-specific antigens have been isolated only incidentally from 
spontaneous human tumors despite intensive continuous efforts (42,43,43a). 
TAA can be divided into oncofetal antigens and tumor-type associated antigens. 
Oncofetal antigens are present in high amounts in malignant and fetal tissues, 
but may also be present in very low amounts in normal tissues (43). Several 
oncofetal antigens have been isolated amongst which the carcinoembryonic 
antigen (CEA) and alpha-fetoprotein (AFP) have been the most thoroughly 
investigated (44). The tumor-type associated antigens are antigens which are 
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present in high amounts in a given type of tumor, but are present in very low 
amounts (or absent) in benign or normal tissue from which the tumor is 
plausibly derived. 
In recent years, numerous MoAb have been manufactured against oncofetal 
antigens and tumor-type associated antigens of melanoma, colorectal cancer, 
prostate cancer and breast cancer ( 45-47). The proteins of the intermediate-
sized filaments form a considerable part of the intracellular matrix. These 
filaments consist of a number of biochemically and immunologically distinct 
proteins which are selectively found in different tissues. Neurofilament protein 
is characteristic for nerve cells, glial fibrilary acidic protein is characteristic for 
astrocytes, desrnin is characteristic for muscle cells, vimentin is characteristic for 
mesenchymal cells and cytokeratins are characteristic for epithelial cells (48). At 
present, a large number of specific and sensitive MoAb to these proteins have 
been developed and are used extensively in diagnostic pathology (47-50). 
1.2.1. Expression of different markers in epithelial skin cancer 
Little is known on the expression of tumor markers in BCC and SCC. Several 
MoAb NE BCC sec Ref. 
TAA 
alpha-fetoprotein (AFP) (+) (59) 
carcinoembryonic antigen (CEA) (+) (58,61) 
? VM-1 + + + (52) 
protein 100, 120 VM-2 + + ? (53,54) 
sialylated Lewisa C241,C50 + + (55) 
sialosyllactotetraose C50 + + (55) 
glycoprotein 280, 500 653.40s + + (56) 
glycoprotein 280, 400 225.28s + + (57) 
? HMB-45 (+) (60) 
Differentiation Antigens (Ag) 
epithelial membrane Ag + (+) (62) 
basal cell Ag + ? (63) 
upper cytoplasmic Ag + (64) 
involucrin + + (65,66) 
pemphigus Ag + (62) 
MHC class I Ag 
HIA-ABC/~2-microglobulin + (+) (+) (67-69) 
Table II. An overview of the expression of tumor associated antigens (TAA),differentiation 
antigens (Ag) and class I antigens of the major histocompaubility c<;>mplex (MHC) 
in normal epidermis (NE), basal cell carcinoma (BCC) and squamous cell 
carcinoma (SCC). + = positive; ( +) = Weakly positive or incidentally positive; - = 
negative; ? = unknown. 
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melanoma-assodated antigens have been defined using MoAb (51). Ruiter et al 
(52) divided the melanoma-assodated antigens into three groups, namely 
differentiation markers, markers assodated with certain stages of neoplastic 
progression and markers assodated with cell function. The third group of 
antigens are involved in immune regulation and belong to the major histo-
compatibility complex (MHC), class I and class II antigens. Both class I and 
class II antigens can be expressed on melanoma cells. However, in epithelial 
skin cancer there are some reports on the presence of TAA which have been 
detected using polyclonal antisera and MoAb (52-61). The expression of TAA 
and differentiation antigens in normal epidermis, BCC and SCC are summarized 
in Table I. The MoAb VM-1 and VM-2 reacted not only with cell membranes of 
epidermal basal cells but also reacted with BCC (52-54). MoAb VM-2 reacted 
with a membranous glycoprotein of molecular weight 100-120 kD (53). The 
MoAb C50 and C241 specific for the carcinoma-associated antigens sialylated 
Lewisa and sialosyllactotetraose resprectively, also reacted with BCC (55). The 
MoAb 653.40s, 225.28s and HMB-45 detecting melanoma-associated antigens 
did not only react with melanomas, but also with some BCC (56,57,60). The 
oncofetal antigens CEA and AFP are not expressed in BCC (59,61). Several 
differentiation antigens, such as epithelial membrane antigen (EMA) (61), 
pemphigus antigen (62), basal cell layer antigens (63), upper cytoplasmic 
antigens (64) and involucrin (65,66) are not expressed in BCC and SCC. 
Furthermore, in BCC (32-microglobulin and HLA-ABC (class I antigens) are not 
expressed (67-69). 
1.2.2. Cytokeratins 
The cytoskeleton of epithelial cells is characterized by the presence of 
numerous bundles of intermediate-sized filaments (tonofilaments), composed of 
a complex family of proteins called cytokeratins (K). They consist of 19 distinct 
polypeptides which are biochemically and immunochemically related and each 
is coded for by a separate gene (70,71). Cytokeratins can be divided into two 
groups; type-I cytokeratins which have an acidic isoelectric point and type-II 
cytokeratins which have a basic isoelectric point (70,72). Cytokeratins can only 
form heteropolymers, i.e. a type-I cytokeratin must combine with a type-II 
cytokeratin to form a filament. In each cytokeratin pair the basic member is 
always about 8 kD heavier than the addic member (72,73). Moll et al (70) 
catalogued human cytokeratins and numbered them from 1 to 19. Cytokeratin 1 
has the highest molecular weight of 67 kD and the highest isoelectric point and 
cytokeratin 19 has the lowest molecular weight of 40 kD and a low isoelectric 
point. 
Specific cytokeratin patterns are characteristic of certain epithelial cell types 
(72). In Figure 1, the distribution of cytokeratins in different epithelial tissues is 
shown. Different cytokeratin patterns have also been observed in different cell 
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Scale I 
52 kD (K8) 
B(ll) 
45 kD (K18) 
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A(l) 
Figure 1. Model of cytokeratin expression proposed by Cooper et al (76).Cytokeratins of the 
Acidic (type 0 and Basic (type m subfamilies are arranged vertically according to 
their molecular weight (see the 5 kD scale).Cytokeratins below the horizontal line are 
mainly expressed by simple epithelia, and those above the line are unique to 
stratified epithelia (s.e.). Dashed box encloses the cytokeratins commonly expressed 
by all stratified epithelia in neoplasms, hyperproliferative diseases and in culture. 
layers of the epidermis and in different adnexal organs of the skin (62,72,74). In 
addition, complex cytokeratin patterns have been observed in certain human 
carcinomas in which the cytokeratin pattern differed from that of the tissue of 
plausible origin (70,75). 
In recent years, a large number of sensitive MoAb to intermediate filaments, 
especially to specific cytokeratins have been produced and extensively used 
(47,50,76-82). The use of anti-cytokeratin MoAb has been found very valuable 
in the differential diagnosis and also allows a further subdivision of carcinomas 
(48,83). 
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1.2.2.1. Expression of cytokeratins in basal cell carcinoma 
The cytoskeleton of tumor cells in BCC is mainly composed of low molecular 
weight cytokeratins (84-87). Various amounts of cytokeratins 5, 6, 8, 14, 15 and 
17 have been isolated from BCC using two-dimensional gel electrophoresis 
(70,86). 
High molecular weight cytokeratins 1, 2 and 10 are expressed in normal 
epidermis but are not expressed in BCC (70,84-86). Cytokeratin 17 is present in 
considerable amounts in BCC and also in the pilosebaceous tract. The absence 
of cytokeratin 17 in the normal interfollicular epidermis suggests that BCC may 
originate from pilosebaceous cells. However, the expression of cytokeratin 17 
in cultured normal skin and in hyperproliferative diseases such as psoriasis has 
also been reported (88,89). The detection of cytokeratin 8 in small amounts in 
some BCC reported by Moll et al is of particular interest (70,86). This low 
molecular weight cytokeratin belongs to the basic group and is normally 
expressed in simple epithelia, in early fetal epidermis and is also observed in 
tumors derived from non-keratinized tissues (75,90). Therefore, it is possible 
that the expression of cytokeratin 8 is a useful marker for these tumors. 
1.3. Tumor immunology 
The role of immunology in cancer has a considerable history dating back to 
the end of the last century. One of the flrst evidence for the existence of a 
host's defence against tumors was reported by Loeb in 1901 (91), who 
demonstrated the rejection of incompatible tumor grafts. A few years later 
Ehrlich (92,93) demonstrated that mice with an established tumor transplant 
often failed to produce an additional tumor when reinoculated with tumor cells. 
This observation suggested the existence of an immune surveillance system. 
Twenty years later it was Murphy (94) who noticed that lymphocytes played a 
role in the resistance to tissue grafts and neoplasia. In the 1940s, the discovery 
of the genetic basis of histocompatibility, specific immunotolerance and the 
graft-versus-host (GVH) reaction led to additional knowledge on the 
immunogenidty of transplanted neoplastic tissues and the host's immune 
response (95). The discovery of the existence of so-called tumor assodated 
antigens (TAA), defined as determinants which are present on tumor cells but 
are either totally absent or present to a limited amount only on normal tissue 
cells, created a new fleld of tumor investigations. Furthermore, TAA of some 
tumors included a subset of cell- surface antigens that were termed tumor-
assodated transplantation antigens (TATA) which were responsible for evoking 
an immune response in other animals syngeneic with the animal in which the 
tumor originated (96). 
Since the etiological agents of tumors arising in humans are often unclear, 
these tumors are classified as spontaneous tumors. In contrast to virus-induced, 
chemically and/or physically induced tumors, spontaneous tumors usually 
express no specific tumor antigens. 
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Clinical observations also support the role of immunologic factors in the 
defence against neoplasia. Organ transplant recipients who received anti-
rejection maintenance dose of immunosuppressants for prolonged periods 
developed more neoplasia than the normal population (29,30,97-99). The 
mechanisms of anti-tumor immune response are rather complex and are as yet 
neither fully elucidated nor understood. However, several subpopulations of T 
cells, cells of the monocyte-macrophage lineage, Natural Killer (NK) cells, B 
cells producing specific and natural cytotoxic antibodies and Killer cells have 
been implicated in the host's anti-tumor immune response (100,101). Especially 
NK cells, probably a subpopulation of lymphoid cells are considered to be the 
first line of defence against tumors (102,103). The recognition and elimination 
of tumor cells by NK cells is not MHC-restricted. 
Since the development of the somatic hybridization technique in 1975 (104), 
many MoAb have been produced which specifically react against membrane 
antigens on different immunocompetent cells. In recent years, several studies 
have been reported on the detailed characterization of the immune infiltrate 
and its possible role in the defence against different neoplasia (105-111). 
1.3.1. Immunology of epithelial skin cancer 
At the end of the last century both Unna and Dubreuilh associated the 
occurrence of skin cancer with the exposure to sun light as a result of 
investigations of individuals with sun-damaged skin (112,113). Forty years later, 
experiments in laboratory mice and rats demonstrated that UV-light was 
responsible for inducing skin cancer (114,115). Moreover, it was shown that 
UV-light had the capacity to act either as an initiator, or as a promotor, or as a 
complete carcinogen (116,117). Kripke and co-workers have made important 
contributions towards the understanding of the effect of UV-light on the 
immune system, especially in relation to skin cancer (118,122). In trans-
plantation studies in syngeneic mice, Kripke showed that UV-induced skin 
tumors were highly antigenic since tumors transplanted to untreated syngeneic 
mice were rejected (118). This rejection was unusual because most mouse 
tumors could be easily transplanted among members of the same inbred mouse 
strain without rejection. However, in mice where the skin had been exposed to 
UV-light, the transplanted tumor were not rejected. Furthermore, UV-induced 
tumors that were implanted in mice whose immune competence was derived 
from normal donors were rejected, in contrast to mice whose immune 
competence was derived from UV-light exposed donors. This indicated a 
systemic effect by UV-light (119,120). T suppressor lymphocytes seemed to be 
responsible for this tolerance-mechanism (121,122). Recently, evidence has 
been presented showing that tumor antigens on UV- induced tuJ;IlorS can be 
divided into tumor-specific transplantation antigens which are targets for the 
immunological effector cells and a common UV-associated antigen recognized 
10 
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by T suppressor lymphocytes which are responsible for the inhibition of tumor 
rejection 023-125). It is not yet clear how and why the UV- associated antigen 
activates the suppressor cell pathway. It has been shown in studies on contact 
hypersensitivity that UV-light inactivates Langerhans cells 026,127). This inacti-
vation leads to a direct or an indirect activation of T suppressor lymphocytes. 
There is evidence that UV-resistant antigen presenting cells, probably Thy-1 + 
cells, activate the suppressor cell pathway 028,129). Prevention of tumor 
rejection may be achieved via the same mechanism (130). 
The relevance of these fmdings in human epithelial skin cancer is at present 
uncertain. It is not known whether the immune system plays as important a role 
in human epithelial skin cancer as in mouse skin cancer. Whether in humans 
suppressor cells are activated following exposure to UV-light, thereby allowing 
the development of epithelial skin cancer, is at present unclear. However, there 
are several observations suggesting that the immune system plays a role in the 
pathogenesis of and the defence against skin cancer. A diminished immune 
responsiveness to dinitrochlorobenzene (DNCB) and standard intradermal 
antigens in sun-damaged skin as compared to non-sun exposed skin has been 
reported 031). Lymphocyte stimulation tests using aquous extracts of epithelial 
skin cancers (e.g. melanoma, SCC and BCC) indicated that the peripheral blood 
lymphocytes of patients were responsive to their respective tumors 032-134). A 
depletion in the surface markers of Langerhans cells in human skin after 
exposure to UV-light has been observed (135). Exposure of human skin to sun 
light for 1 hour/day for more than 12 consecutive days led to decreased 
numbers of total circulating T cells and a decrease in the T helper and T 
suppressor/cytotoxic (TH/Ts;c) ratio 036). Similar decreases in TH/Ts;c ratios 
and delayed hypersensitivity reactions to DNCB have been observed following 
solarium exposure 037). Furthermore, a decreased natural killer cell activity 
after exposure to UV-light has been reported (138). Finally, the presence of an 
inflammatory mononuclear infiltrate consisting mainly of T cells in epithelial 
skin cancer indicated a cell-mediated immune response. In melanoma (139) and 
in BCC 040), an association was observed between heavy lymphocytic 
infiltration and partial regression of the tumors indicating an important role of 
the immune system in the defence against these tumors. 
1.3.2. Immune response in basal cell carcinoma 
Immunological studies in patients with BCC have demonstrated several 
abnormalities. Dellon et al (141) observed a low T cell level in the peripheral 
blood of patients with BCC of large size (>2cm in diameter) and aggressive 
growth pattern. A statistically significant decrease in the T J/T s;c ratio in patients 
with BCC as compared to healthy controls has been reported (142). The 
proliferative responses of lymphocytes to common mitogens were decreased in 
patients with multiple or aggressive BCC, while in patients with BCC without 
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aggressive growth pattern, the proliferative responses of lymphocytes were 
normal (143,144). The number of T cells and the lymphocytic proliferative 
responses decrease with increasing age (145,146). Therefore, the development 
of BCC in older patients may be influenced by a decreased immune 
surveillance capadty as a result of the physiological aging process. There are 
apparently conflicting reports on the lymphocytic responses in BCC 
(134,147,148). Aquous extracts prepared from BCC cells when incubated with 
peripheral blood lymphocytes of healthy individuals inhibited their proliferative 
responses (148). However, incubation of peripheral blood lymphocytes from 
BCC patients with aquous extracts of BCC increased the lymphocytic proliferati-
ve response in 3 out of the 8 cases (134). These contradicting results may be 
explained by the results of Sheretz et al (147) who noted that only the extracts 
prepared from BCC with aggressive biological behaviour inhibited the 
autologous lymphocytic proliferative response while no inhibition occurred 
using extracts from non-aggressive BCC. 
Macrophages may act as anti-tumor effector cells (149,150). In patients with 
BCC a defective macrophage mobilization has been observed (151,152). It has 
been suggested that soluble factors released by the tumor cells may inhibit the 
accumulation of macrophages at the site of such tumors. This inhibition can 
interfere with tumor antigen-processing and/or tumor cell killing, thus allowing 
more aggressive tumor growth. 
In the last decade, several reports on the local immune response have been 
published in which attempts were made to eluddate the function of the cellular 
inflammatory infiltrate surrounding BCC and its possible role in the control of 
tumor growth (105,153-156). The peritumoral inflammatory infiltrate consisted 
mainly of T cells (105,153,154). A considerable number of immunoglobulin-
bearing cells in the infiltrate were also observed (153,155). Using the E-rosette 
test and the EAC-rosette test, Viae et al (153) observed a T/B ratio of 4.6 in the 
inflammatory infiltrate eluted from BCC. Synkowski et al (156), using a panel of 
MoAb, observed a T/B ratio of 1.0 in situ. These results may suggest a 
significant role of the humoral response in BCC. However, Eaglstein et al (105) 
reported that the infiltrate in BCC consisted of 90o/o T cells and less than 10o/o B 
cells, which suggested a minor role of the humoral immune response. 
Furthermore, to date no circulating antibodies against BCC have been isolated. 
Therefore, the role of humoral immunity in the defence against BCC is rather 
doubtful. Little is known about the presence and the role of NK cells in 
epithelial skin cancer. Recently, Kohchiyama et al reported on the presence of 
NK cells in SCC (109). They suggested an important role of NK cells in the 
defence against SCC, but not against BCC. 
1.4. Objectives of the study 
The main aims of the investigations reported in this thesis were to obtain 
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detailed insight into the immunopathology of BCC which exhibit a broad 
spectrum of clinical and histological appearances. Two lines of investigations 
were followed. The frrst line concerned a search for useful tumor markers for 
BCC. Although the histological diagnosis of BCC is uncomplicated, in certain 
instances in order to establish a diagnosis, it would be advantageous if useful 
tumor markers for BCC were abailable. One such marker that was investigated 
was cytokeratin 8 (see§ 1.2.2.1). 
The second line of investigation concerned the characterization of the 
inflammatory infiltrate in BCC. Previously reported studies (105,153-156) on the 
characterization of the immune infiltrate in BCC were inconclusive and contro-
versial, especially concerning the composition of the infiltrate and the role of 
humoral immunity. Therefore, investigations were undertaken to obtain a 
detailed insight into the composition of the peritumoral inflammatory infiltrate 
and its possible role in the defence against not only BCC, but also Bowen's 
Disease (carcinoma in situ). 
In recent years, several biological response modifiers, e.g. interferons (alpha, 
beta, gamma), interleukin-2 and tumor necrosis factor with anti-proliferative 
properties have become abvailable and their therapeutical potential in anti-
cancer therapy has received much attention. There is evidence for an immune 
response, although not adequately functioning, against BCC. Since new 
approaches to therapy, especially in selected cases of BCC, may be of 
advantage, a clinical pilot study was undertaken to investigate the efficacy of 
human recombinant interferon-gamma in patients with BCC. 
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Basal cell determinants in human basal cell carcinomas 
ABSTRACf 
This report deals with the reaction pattem(s) of two monoclonal antibodies 
(MoAbs) with normal skin and basal cell carcinomas (BCC). Using indirect 
immunoperoxidase (IIP) and indirect immunofluorescence (IIF) techniques, 
MoAb 12 G7 was observed to react with a determinant related to the cell 
membrane of the epidermal basal cells. In the IIP technique MoAb 12 G7 
showed a positive reaction with 32 out of 34 BCC (94%), while in IIF all the 14 
BCC that were studied were positive. In most cases only the cells at the 
periphery of the tumour nests were stained. MoAb 253 B7 reacted with 
cytoplasmic deterrninant(s) of the epidermal basal cells both in the IIF as well 
as in the IIP techniques. Using the liP technique only 5 out of 34 BCC (15%) 
showed a positive reaction with this MoAb. Four· of the 5 positively staining 
tumours showed aggressive histological features. Using IIF technique only 2 out 
of 14 BCC were positive. The results presented in this communication are 
discussed with regard to the possible expression of selective differentiation and 
tumor-assodated deterrninant(s) in BCC. 
INTRODUCTION 
Basal cell cardnoma (BCC) is the most common cancer of epithelial origin 
although metastasis is fortunately extremely seldom (15, 23, 30). However, a 
proportion of BCC depending on the specific histologic features are aggressive 
in their behaviour: local destruction leading to mutilation and recurrence after 
surgical exdsion (11, 15, 26). It is well known that in malignant epithelial skin 
tumours differentiation antigens, such as pemphigus antigen (3), basal cell layer 
antigens (2), upper cytoplasmic antigens (33), Pz-microglobulin (7, 10, 14, 29) 
and involucrin cannot be detected (20, 25). As in other neoplastic diseases, in 
epithelial skin tumours too, there are some reports on the presence oftumour-
associated antigens (TAA) recognized by monoclonal antibodies (MoAbs), 
which form an additional aid for the detection of residual tumour cells in Mohs' 
surgery (1, 19, 22). Investigations, into the cytokeratin composition of normal 
and neoplastic epithelium have provided insight into the pathogenesis (16, 17, 
18, 31, 32). The exclusive expression of cytokeratin 17 in BCC and 
pilosebaceous tract and not in the normal interfollicular epidermis has been 
reported previously by Moll et al. (17). This would suggest that the origin of 
BCC is related to pilosebaceous cells. However, the expression of keratin 17 in 
cultured normal skin, conjunctival and esophageal keratinocytes, and in 
hyperproliferative epidermal diseases such as psoriasis have all been previously 
reported (4, 16, 27, 31). Therefore as stated by Weiss et al. (31), the expression 
of keratin 17 is not cell-type spedfic and its presence in BCC should not be 
taken as evidence for a pilosebaceous origin of the tumour. 
The lack of insight into the pathogenesis of BCC, the spectrum of various 
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clinical and histological appearances of BCC (15, 30) and the diagnostic 
problems associated with some histological types of BCC (13, 15) formed the 
basis of the current investigations. Recently we reported on the reaction 
patterns of MoAbs 12 G7 and 253 B7 in normal and psoriatic skin (28). In the 
present study these two MoAbs were used for investigation into basal cell 
determinant(s) of BCC. 
MATERIALS AND METHODS 
Preparation of skin samples 
Thirty-four specimens of basal cell carcinomas (BCC) and surrounding 
normal skin were obtained by surgical excision from 29 patients aged 35 to 88 
years. The diagnosis of the tumours were confirmed by examination of 
haematoxylin and eosin (H & E)-stained frozen sections and stained paraffin 
embedded sections. The BCC were classified in the conventional manner as 
described previously (12, 15). For the histopathological examination of the skin 
adjacent to the tumour, the samples were cut in their length in two equal parts. 
One portion and the edges of the other portion were fixed in formalin and 
paraffin embedded for histological confirmation of diagnosis and for 
determination of tumour free margins. The remaining portion was frozen in 
liquid nitrogen-cooled isopentane and stored in liqued nitrogen. Cryostat 
sections (5 !lffi in thickness) were placed on alcohol-cleaned glass slides, air 
drie dand fiXed in acetone for 10 min at room temperature. Sections were air-
dried and stained immediately for the indirect immunoperoxydase (liP) 
procedure or for the indirect immunofluorescence (IIF) procedure. Normal skin 
samples were obtained from 10 healthy volunteers and were processed in the 
same way. 
Monoclonal antibodies 
MoAb 12 G7 was generated after three intraperitoneal immunizations of 
BALB/C mice with 1x107 cells from primary culture of human mesothelioma. 
Spleen cells from immunized mice were hybridized with SP2/0 cells using the 
somatic hybridization techniques (9). The hybridoma supernatants were 
prescreened using the st;mdard ELISA technique and cultured mesothelioma 
cells. They were also prescreened on cryostat skin sections using IIF technique. 
MoAb 253 B7 was obtained after three intraperitoneal immunizations of BALB/C 
mice with an extract of total tumour material of human skin squamous cell 
carcinoma, prepared using an ultra-Turrax homogenizer. Spleen cells from 
immunized mice were hybridized with P3 myeloma cells (9). The hybridoma 
supernatants were prescreened on cryostat sections of normal skin and 
squamous cell carcinoma using liP technique. MoAb 253 B7 was subcloned 
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twice and 107 cells were injected intraperitoneally in BALB/C mice. After 10 
days the asdtes fluid was collected. A titer of 1:1200 was used in the liP and IIF 
techniques.The results of prescreening showed that the 2 MoAbs reacted with 
the basal cell layer of normal epidermis. The 2 MoAbs were produced at the 
Dept. of Cell Biology and Genetics. 
Indirect immunofluorescence test {llF) 
The staining pattern of the epidermis adjacent to the tumour and the 
epidermis at a distance (>150 J.Lm) was studied in 14 BCC. Dry fiXed cryostat 
sections were preincubated for 30 min with a 1:20 dilution of bovine serum 
albumin (BSA) to reduce aspecific staining. The sections were then incubated 
for 60 min at room temperature with one of the MoAbs, rinsed with phosphate-
buffered saline (PBS, pH 7.4) and incubated for 30 min with Fluorescein 
isothiocyanate (FITC) labelled rabbit-antimouse IgG (Dakopatt, Copenhagen, 
Denmark) at a dilution of 1:50. 
The sections were then rinsed with PBS and mounted in glycerol-PBS (9:1) 
solution. A Leitz Ortholux fluorescence microscope equipped with filters for 
epi-illumination and narrow band exdtation was used for examining the 
sections. 
Indirect immunopero:xidase test (liP) 
The cryostat sections were preincubated with BSA at a dilution of 1:20 for 30 
min. The sections were then incubated with one of the MoAbs for 60 min, 
rinsed in PBS and incubated with rabbit peroxidase-conjugated antimouse IgG 
at a dilution of 1:50. The peroxidase reaction was developed by incubating the 
sections with 3,3'-diaminobenzidine (DAB) at a concentration of 0.5 mg/ml and 
hydrogen peroxide (0.01 %) for several minutes at room temperature. Sections 
were then rinsed in tap water, counterstained with haematoxylin for 1-2 min 
and rinsed again in tap water. The sections were mounted in Malinol (Chroma-
Gesellschaft, Stuttgart). All sera were diluted in PBS, pH 7.4. 
In both procedures the controls comprised: antikeratin MoAbs KSO (Sanbio 
b.v., Uden, The Netherlands) and K92 (Dakopatts, Holland) were used as 
positive controls (21, 24) and negative controls were· performed by omitting 
either the primary antibody or the rabbit-antimouse immunoglobulin. 
RESULTS 
Normal skin 
In the 10 normal skin samples MoAb 12 G7 reacted consistently with 
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Fig.lNormal skin cryostat section (5 JLm) MoAb 12 G7, liP technique. x340. 
Tbe staining is confined to the membrane region of the epidermal basal 
cells. 
Fig.2. Normal skin cryostat section (5 JLm) MoAb 253 B7, liP technique. x340. 
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membrane related determinant(s) of epidermal basal cells as observed in the IIF 
and liP (Fig. 1). MoAb 12 G7 also showed a positive reaction with the outer 
root sheath of the hair follicles, sebaceous glands and the ducts and the 
secretory portions of the sweat glands. MoAb 253 B7 showed consistently a 
diffuse staining of the cytoplasm of the epidermal basal cells (Fig. 2) and also 
stained the outer root sheath of the hair follicles, sebaceous glands, sweat 
glands, espedally the ducts and the myoepithelial cells of the secretory ducts, 
smooth muscle fibers of blood vessels and musculi arrector pili. 
Basal cell carcinomas (BCC) 
Thirty-four BCC from 29 patients were evaluated. Twenty-eight were located 
in head and neck region, four were in the trunk region and two were located 
on one of the extremities. The histological subclassification of BCC is 
summarized in Table I. Table II shows a summary of the reactivity pattern of 
MoAbs 12 G7 and 253 B7. 
Table I Histological subclassification of 34 basal cell carcinomas from 29 patients. 
Histological type 
Solid 
Keratotic 
Cystic 
Adenoid 
Infiltrating 
Morphoeic 
Superficial 
Pigmented 
Basosquamous 
Number of tumours 
16 
2 
2 
2 
5 
3 
1 
2 
Table II. Reactivity patterns of monoclonal antibodies (MoAbs) 12 Gland 253 Bl in nonnal 
skin and basal cell carcinomas 
MoAb NE Tumour EPA EPD Staining technique 
12G7 10/10 32/34 34/34 34/34 TIP 
10/10 14/14 14/14 14/14 IIF 
253 B7 10/10 5/34 34/34 34/34 TIP 
10/10 2/14 13/14 14/14 IIF 
NE = no. of normal skin biopsies which showed positively staining basal cell layer, EPA = 
no. of tumours in which the epidermis adjacent to the tumour showed positive staining, EPD = 
no. of tumours in which the epidermis distant from the tumour showed positive stanining. 
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MoAb 12 G7: in the liP, 32 out of 34 BCC (94%) stained positively. The 
peripheral cell layers of most tumour nests stained strongly, whereas the center 
of the tumour nest stained either very weakly or none at all (Figs. 3a and 3b). 
In the IIF all 14 BCC evaluated were positive. 
MoAb 253 B7: only 5 out of 34 BCC (15%) stained positively in the liP. All 
tumour cells in the tumour nests and strands of tumour cells were stained, 
except the tumour cells with squamous-like differentiation in the keratotic BCC 
and in the basosquamous BCC (Fig. 4). The other 29 BCC stained either very 
weakly or none at all. The 5 positively staining tumours comprised 2 morphoeic 
type, 1 keratotic type, 1 fibrosing infiltrated type and 1 basosquamous type. 
Both in the IIF and in the liP no diminishing staining was observed adjacent to 
the tumour. The IIF staining pattern is shown in Fig. 5. 
Fig. 3a and 3b. Cryostat sections (5 J.Lm) of solid type BCC and infiltrating type 
BCC respectively, MoAb 12 G7, liP technique. X340 and x135, 
respectively. Tumour cells at the periphery of the tumour nests 
are predominantly stained (arrows). 
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Fig.4. Cryostat section (5 Jlm) of basosquamous BCC, MoAb 253 B7, liP 
technique. x340. Tumour cells at the periphery stain strongly (an-ow) 
whereas squamous-like cells in the center of the tumour nests remain 
unstained. 
Fig.5. 
Cryostat section (5 Jlm) of 
solid type BCC, MoAb 253 
B7, IfF technique. x340. The 
epidermis nearby the tumour 
showed a strong staining 
with an abrupt change to no 
staining of the adjacent 
tumour cells (arrows). 
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DISCUSSION 
The results of this report show that MoAb 12 G7 and 253 B7 reacted with 
different determinants of the epidermal basal cells. MoAb 12 G7 probably 
reacted with a membrane related determinant and MoAb 253 B7 reacted with a 
cytoplasm determinant Both MoAbs did not react exclusively with skin 
epithelium; 12 G7 reacted with mesothelium and 253 B7 with smooth muscle 
cells and myoepithelial cells. In the current studies we observed that MoAb 12 
G7 reacted positively in 32 out of 34 BCC (94%) and MoAb 253 B7 reacted 
positively only in 5 out of 34 BCC (15%). There are several reports in the recent 
literature concerning MoAbs VM-1 (22), VM-2 (19) and PKK-2 (8), which react 
with normal epidermal basal cells and BCC. Eto et al. (5) described MoAb 
EKH4 which reacted with the lower 2-3 cell layers of the normal epidermis and 
upon immunoblotting was found to react predominantly with a 50 KD keratin. 
MoAb EKH4 also reacted positively with BCC. Each of the above mentioned 
MoAbs reacted consistently with all the tumour nests of BCC. However, in the 
present study, using MoAb 12 G7 only the cells at the periphery of the tumour 
nests were strongly stained, whereas the cells at the center of the tumour nests 
were either stained very weakly or not at all. In most cases, the tumour cells in 
the center of the tumour nests showed on light microscopical level aspects of 
differentiation (elongated cells with an oval pale nucleus). The differentiated 
tumour cells in keratotic BCC and basosquamous BCC also did not react with 
MoAb 12 G7. A possible explanation for this observation might be that the 
tumour cells, which show some degree of differentiation, may have lost this 
determinant(s) as compared to that observed in suprabasal cell layer of normal 
epidermis. Another explanation may be that the tumour cells at the center of 
the tumour nests become less vital and lose some markers due to physiologic 
factors, such as diminished availability of nutrients. In this respect the findings 
recently reported by Grimwood et al. (5) are of particular interest They 
observed that dividing cells in nodular BCC were mostly located at the 
periphery of tumour nests. The cells in the center of the tumour nests had lost 
their capacity to divide and had undergone some type of differentiation similar 
to normal epithelial cells. 
MoAb 253 B7 reacted only with 5 out of 34 BCC (15%). Conspicuously 4 out 
of 5 positively staining tumours were of aggressive type. The other 29 out of 34 
BCC stained either very weakly or not at all. Probably the cytoplasmic determi-
nant is not lost but there -is a variation in the quantity of the expression of this 
determinant in BCC. Whether the quantity of expression of this determinant is a 
marker for the aggressive behaviour is subject to speculation, especially, since 6 
out of 10 tumours with aggressive histological features did not stain positively. 
The exact nature of the determinants detected by the two MoAbs 12 G7 and 
253 B7 is currently under investigation. However, our present results lead to the 
conclusion that the MoAbs 12 G7 and 253 B7 detect different determinants in 
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basal epidermal cells and tumour cells of BCC. Therefore, these two MoAbs 
may be helpful in eluddating the pathogenesis of basal cell carcinomas. 
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Cytokeratins in human basal cell carcinoma 
ABSTRACT 
The expression of the low molecular weight cytokeratins (K) 7,8,18, 19 and 
the high molecular weight cytokeratin 10 in 21 basal cell carcinoma (BCC) was 
studied using seven different monoclonal antibodies (MoAbs) with specific 
anticytokeratin activity. MoAbs RCK 105 (anti-K7), RPN 1164 (anti-low 
molecular weight cytokeratins of basic group), Ks 19.1 (anti-K19) and Cam 5.2 
(anti-K8, K18, K19) reacted positively but inconsistently in the BCC that were 
examined. MoAbs 1166 (anti-K8) and RGE 53 (anti-K18) did not react at all. 
MoAb RKSE 60 (anti-K10) did not react with the tumor cells. From the results of 
this study, it can be concluded that cytokeratins 7 and 19 are expressed in BCC 
(43% and 71%, respectively), whereas cytokeratin 8 is not expressed. 
INTRODUCTION 
Basal cell carcinomas (BCC) show a wide spectrum of clinical and 
histological appearances (1-3). As far as the origin of BCC is concerned, it is still 
not clear whether they are derived from skin adnexal organs or from 
transformed basal cells of the interfollicular epidermis. The first hypothesis is 
supported by the observation that histologically BCC can show patterns of 
differentiation analogous to different structures of skin adnexal organs (2, 4). 
Moreover, upon biochemical analysis of cytokeratins, Moll et al (5) observed 
the expression of cytokeratin 17 in BCC and pilosebaceous tract but not in the 
normal interfollicular epidermis. This would imply that BCC may be derived 
from pilosebaceous cells. However, the expression of cytokeratin 17 in cultured 
normal skin and in hyperproliferative diseases such as psoriasis has been 
reported (6, 8). Therefore, this cytokeratin is not cell-type specific and its 
presence in BCC cannot be regarded as evidence for a pilosebaceous origin of 
the tumor. In addition to cytokeratin 17, cytokeratins 5 and 14 are the main 
constituents of BCC. These two cytokeratins are also expressed in normal 
interfollicular epidermis and adnexal organs (5, 7). The second hypothesis is 
supported by the observation that many basal cell carcinomas show no clear 
contact with skin adnexal organs, e.g. in the superficial type of BCC, tumor 
buds are only observed in close contact with the basal layer of the epidermis. It 
is of particular interest that, using two - dimensional gel electrophoresis, 
cytokeratin 8 was detected in small amounts in some BCC but not in normal 
epidermis (7). This cytokeratin is normally expressed in simple epithelia and is 
also observed in tumors derived from nonkeratinized tissues and early fetal 
epidermis (9, 10). 
Recently, since a number of specific monoclonal antibodies against 
individual cytokeratins have become commercially available, it has become 
possible to classify and catalogue the distribution of cytokeratins in various 
dermatological diseases including the disorders of keratinization and epithelial 
skin tumors. 
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In this communication, we report on the distribution of the low molecular 
weight cytokeratins 7, 8, 18, 19 and the high molecular weight cytokeratin 10 in 
BCC using an indirect irnrnunoperoxidase technique and monoclonal antibodies 
of specific anti-cytokeratin activity. 
MATERIAlS AND METHODS 
Twenty-one specimens of basal cell carcinoma (BCC) were surgically excised 
from 20 patients aged 33 to 81 years. The diagnoses of BCC were confirmed by 
examination of haematoxylin and eosin (H&E) - stained frozen sections and 
stained paraffin embedded sections. The BCC were classified in the 
conventional manner as described previously (3, 4). For the histopathological 
examination of the tumor and the skin adjacent to it, the samples were cut 
lengthwise in two equal parts. One portion and edges of the other portion were 
fixed in formalin and paraffm embedded for histological confirmation of 
diagnosis and for determination of tumor free margins. The remaining portion 
was frozen in liquid nitrogen-cooled isopentane and stored in liquid nitrogen. 
Serial cryostat sections, 5 jlffi thick, were placed on alcohol- cleaned glass 
slides, air dried and fixed in acetone for 10 min at room temperature and 
stained using the procedure described in our previous study (11). Briefly, the 
cryostat sections were preincubated with 5% (W N) bovine serum albumin in 
phosphate-buffered saline (PBS, pH 7.4) for 30 min. The sections were then 
incubated with an optimal dilution of one of the monoclonal antibodies 
(MoAbs) with anti- cytokeratin reactivity for 60 min. The specificity of the 
MoAbs is shown in Table I. Sections were then rinsed in PBS and incubated 
with rabbit peroxidase - conjugated anti - mouse IgG (Dakopatts, Amsterdam, 
The Netherlands) at a dilution of 1:50. The peroxidase reaction was developed 
by incubating the sections with 3,3' - diaminobenzidine (Sigma Chemical Co., 
Amsterdam, The Netherlands) at a concentration of 0.5 mg/ml and 0.01% 
hydrogen peroxide for 10 min at room temperature. Sections were then rinsed 
in tap water, counter- stained with haematoxylin for 1-2 min and rinsed again 
in tap water. The sections were mounted in Malinol (Chroma - Gesellschaft, 
Stuttgart). The negative controls comprised either the omission of primary 
antibody or rabbit anti- mouse immunoglobulin. 
RESULTS 
Twenty-one basal cell carcinomas (BCC) from 20 patients were evaluated. 
Sixteen were located in the head and neck region, 4 were in the trunk region 
and 1 was located on one of the upper arms. From the 16 BCC in the head and 
neck, 4 were located in the temporal region, 3 were located on one of the 
cheeks, 1 was retroauricular, 2 were paranasal, 2 were on the forehead, 2 were 
on the nose tip, 1 was on the upper lip and 1 was in the neck. The histological 
classification of the 21 BCC showed that 8 were solid type, 7 were infiltrating 
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Cytokeratins in human basal cell carcinoma 
Figure la + lb. Cryostat sections (5Jl.m) of infiltrating type basal cell 
carcinoma, MoAb RCK 105 (anti-K7), IIP technique, x 135 and x340 
respectively. An inconsistent expression of cytokeratin 7 is seen between 
and within various tumor nests. Tbe staining pattern of MoAb RPN 1164 
(anti-low molecular weight cytokeratins of basic group) was identical. 
type, 2 were adenoid type, 1 was superficial type, 1 was cystic type and 2 were 
morphoeic type. 
Table II shows the individual reactivity pattern of the MoAbs RCK 105, RPN 
1166, RPN 1164, Cam 5.2, RKSE 60, RGE 53 and Ks 19.1 in each of the 21 BCC. 
It can be seen that MoAb RCK 105 stained more than 5% of the tumor cells in 9 
out of 21 (43%) BCC. An example of the staining pattern is shown in Figure la 
and lb. In the remaining 12 BCC incidental or no staining of the tumor cells 
was observed. MoAb RPN 1166 did not stain the tumor cells in any of the 21 
BCC that were examined, but sweat glands were stained in all cases. MoAb RPN 
1164 stained more than 5% of the tumor cells in 11 out of 21 (52%) BCC. The 
staining pattern was identical to that observed using MoAb RCK 105. MoAb 
Cam 5.2 stained more than 5% tumor cells in 16 out of 21 (76%) BCC. It also 
reacted with the upper cell layer of stratum spinosum and stratum granulosum. 
MoAbs RKSE 60 and RGE 53 did not react at all with the tumor cells in any of 
43 
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Figure 2a + 2b. Cryostat sections (5 J.Lm) of infiltrating type basal cell 
carcinoma, MoAb .Ks 19.1 (anti-K19), IIP technique, x135 and x3 4 0 
respectively. More than 75% of the tumor cells were stained. The reactivi-
ty pattern of MoAb Cam 5.2 (anti-KB, K18 and K19) was identical. 
the 21 BCC that were examined, but reacted in all cases with the suprabasal cell 
layer of the epidermis and the sweat glands respectively. MoAb Ks 19.1 stained 
more than 5% of the tumor cells in 15 out of 21 (71%) BCC. An example of the 
staining pattern is shown in Figure 2a and 2b. 
In Table III, the reactivity patterns of the seven MoAbs are summarized 
When the percentages of the positively stained tumor cells are divided into five 
categories, it can be seen that the reactivity pattern of MoAbs RPN 1164, RCK 
105, Cam 5.2 and Ks 19.1 are inconsistent. There was no correlation between 
the expression of cytokeratins 7 and 19 ~d the sex or the age of the patients, 
or the location or the histological type of BCC. 
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DISCUSSION 
Extensive investigations have demonstrated that low molecular weight 
cytokeratins 7, 8, 18 and 19 which are characteristic for simple epithelia are not 
expressed in stratified epithelia (7). However, using biochemical techniques, 
cytokeratins 8 and 19 were demonstrated in esophagus carcinomas and 
squamous cell carcinoma of the rectal - anal region and cytokeratins 7, 8 and 19 
in cloacogenic carcinoma. In addition, a limited amount of cytokeratin 8 was 
detected in some basal cell carcinomas (BCC) but not in normal human 
epidermis (7, 9). 
The main objective of the investigations presented here was to determine 
whether cytokeratin 8 could be detected in BCC using an indirect 
immunoperoxidase technique. The results of this study showed that using 
MoAb RPN 1166 the expression of cytokeratin 8 was not observed in any of the 
BCC that were examined. This discrepancy may be due to the differences in the 
techniques. Alternatively, the epitope that the MoAb RPN 1166 detects in 
immunoblotting studies is not detected in cryostat sections using immuno-
peroxidase technique. 
Contrary to the results of biochemical studies, in this study cytokeratins 7 and 
19 were expressed in BCC. However, their expression was inconsistent between 
and within various tumor nests of any particular BCC. A correlation between 
the particular histological type of BCC and the expression of the cytokeratins 
was not observed. There was no correlation between the expression of 
cytokeratins 7 and 19 and the location of the tumor, or with the sex and the age 
of the patients. Recently, it has been reported that cytokeratin 19 was expressed 
in a BCC showing an eccrine differentiation (12). Bartek et al (13) recently 
reported on the reactivity of two MoAbs against cytokeratin 19 in human 
tumors. However, these two MoAbs did not detect. cytokeratin 19 in the two 
BCC that were examined. Their results therefore must be considered as 
preliminary, since only two BCC were examined. 
The expression of cytokeratin 18 was not observed in any of the BCC using 
MoAb RGE 53, in the present study. This confirms the previous observations by 
Debus et al (14). Two reports (14, 15) have been published on the presence of 
low molecular weight cytokeratins in BCC. However, the MoAb 16a used by 
Knight et al (15) did not react exclusively with cytokeratin 18, but also reacted 
with cytokeratin 17. The latter cytokeratin is present in a considerable amount 
in BCC (5). Thomas et al (16) reported on the presence of a 45 Kd cytokeratin 
in BCC and in the basal cell layer of normal human epidermis. However, their 
results were based on studies with formalin - fixed tissues. In addition, for 
preparing antibodies to individual cytokeratins, they used proteins which were 
extracted from human stratum corneum. Since a 45 Kd cytokeratin has not 
been detected in stratum corneum or even in normal epidermis, the specificity 
of the antiserum for the 45 Kd cytokeratin is uncertain. 
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The slight differences between the reaction patterns of MoAbs Cam 5.2 and 
Ks 19.1 in the present study can be explained on the basis of the detection of 
different epitopes of cytokeratin 19. Since MoAb Cam 5.2 was observed also to 
react with the upper cell-layers of the stratum spinosum and the stratum 
granulosum, it seems likely that this MoAb has additional activity. Similar slight 
differences between the reaction patterns of MoAbs RPN 1164 and RCK 105 
were also observed, which could be explained on the basis of the detection of 
different epitopes of cytokeratin 7. Alternatively, MoAb RPN 1164 could detect 
an epitope of cytokeratin 8, which cannot be detected by MoAb RPN 1166 
(anti- cytokeratin 8). 
The inconsistent expression of cytokeratins 7 and 19 in the present study 
may be due to the variability in the expression of cytokeratins as a result of the 
heterogeneity of the tumor cells of BCC. There is evidence that tumors are 
heterogeneous and that different sub-populations may express different 
antigens (17). The results of the present study also support the concept that 
during cellular transformation and tumor development, a switch occurs in 
favour of the expression of low molecular weight cytokeratins 7 and 19 in BCC. 
Since low molecular weight cytokeratins are expressed in early fetal skin (10), it 
is conceivable that only that sub-population of tumor cells that has reverted 
back to its fetal form expresses these cytokeratins. 
At the present time, moreover, the possibility cannot be totally excluded that 
the inconsistent expression of cytokeratins 7 and 19 observed in the current 
studies is due to the limited sensitivity of the immunoperoxidase technique. In 
our previous studies (11, 18), we used the indirect immunofluorescence (IIF) 
technique and the indirect immunoperoxidase (liP) technique simultaneously. 
In those studies the liP-technique was observed to be more sensitive and 
reproducible in our hands than the IIF- technique. Indeed, further investigations 
using a more sensitive technique such as immuno-electron microscopy should 
elucidate whether the expression of cytokeratins 7 and 19 in BCC can be 
regarded as suitable markers. 
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ABS1RACT 
Ultrastructural investigations into the location and the expression of the 
cytokeratins 7, 8, 10 and 19 were undertaken on ultrathin cryosections of 8 
basal cell carcinomas (BCC) using a high resolution immunogold labeling 
method and five different monoclonal antibodies against specific cytokeratins. 
The results showed that cytokeratin 10 was expressed only in the differentiated 
keratinocytes. In contrast to the previously reported biochemical and 
immunohistochemical studies, in this study cytokeratin 19 was expressed not 
only in the tumor cells of BCC but also in the normal epidermal keratinocytes. 
The expression of cytokeratin 7 in BCC could not be confirmed but the lack of 
expression of cytokeratin 8 was confirmed, excluding its potential role as a 
specific histopathological marker for BCC. 
INTRODUCTION 
The intermediate-sized filaments of human epithelial cells are composed of 
various keratin-like proteins called cytokeratins. They constitute a family of 19 
biochemically and immunologically related polypeptides. These polypeptides 
can be divided into two groups; type-I cytokeratins which have an acidic 
isoelectric point and type-II cytokeratins which have a basic isoelectric point (1, 
2). These cytokeratins can only form heteropolymers, i.e. a type-I cytokeratin 
must combine with a type-II cytokeratin to form a ftlament. In each cytokeratin-
pair the basic member is always about 8 kilo dalton heavier than the acidic 
member (2, 3). Specific cytokeratin patterns are characteristic of certain 
epithelial cell types (1). Moreover, different cytokeratin patterns have also been 
observed in different cell layers of the epidermis and in different skin adnexal 
organs (1, 2, 4). Various amounts of cytokeratins 5, 6, 8, 14, 15 and 17 have 
been isolated from basal cell carcinoma (BCC) using two-dimensional gel 
electrophoresis (1, 5). The expression of cytokeratin 8 in some BCC which was 
demonstrated using biochemical techniques is of particular interest, since this 
cytokeratin is not expressed in normal human epidermis and in skin adnexal 
organs, but it is expressed in simple epithelia and early fetal skin (1, 6, 7). 
Recently, we reported on the distribution of low molecular weight 
cytokeratins 7, 8, 18, 19 and the high molecular weight cytokeratin 10 in 21 
BCC using an indirect immunoperoxidase technique and monoclonal antibodies 
of specific anti-cytokeratin activity (8). In that study it was observed that 
cytokeratin 8 was not expressed in any of the 21 BCC that were examined. 
However, cytokeratins 7 and 19 were expressed inconsistently in 10 of the 21 
(48%) BCC. 
The aim of the present study was to investigate whether the results of our 
recent study (8) could be confirmed using immunoelectron microscopy, and to 
try to resolve the discrepancy concerning the expression of cytokeratin 8 in 
BCC observed in the previously reported biochemical studies (1, 5) and in our 
recently reported light microscopy study (8). 
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MATERIALS AND METIIODS 
Tissue preparation. Eight 4 mm punch biopsies of basal cell carcinoma (BCC) 
were obtained from 2 females and 5 males aged 37 to 82 years. The biopsies 
were cut lengthwise into two equal parts. One part was fixed in formalin and 
paraffm embedded. Histological confirmation of the diagnosis was obtained by 
examination of haematoxylin and eosin (H&E) - stained sections. The BCC were 
classified in the conventional manner as described previously (9, 10). The 
remaining part was processed using the method described previously (11) with 
some modifications. Briefly, it was fixed by immersion in 2% paraforrnaldehyde 
and kept for 7 days at 4° C. Tissue blocks ( < 1 mm3) were transferred to a 
conservation fixative solution containing 33.9% (W IV) sucrose and 1% 
paraformaldehyde. They remained in this solution until ultrathin sections were 
cut. Two hours prior to sectioning, the tissue blocks were transferred into a 25% 
(W IV) polyvinyl pyrolidone solution (PVP) containing 0.04 M sodium carbonate 
and 2.3 M sucrose. All solutions were prepared in 0.1 M phosphate buffer, pH 
7.2. 
Ultracryotomy. Ultrathin cryosections (gold to blue interference colours) were 
cut with glass knives using a LKB Cryo-nova ultramicrotome (LKB, The 
Netherlands) at -90°C to -ll0°C and transferred to carbon coated formvar fllmed 
200 mesh copper grids in 2 mm wire loop with a droplet of 2.3 M sucrose. The 
grids were then transferred to a droplet of 2% (W IV) gelatine solution for a 
minimum of 5 minutes to remove the sucrose. 
Immunogold labeling. All incubations were performed at room temperature 
and all sera were diluted in phosphate-buffered saline (PBS, pH 7.2). Initially, 
all grids were rinsed 3 times with a droplet of PBS containing 0.2% (W!V) 
glycine. The sections were then incubated for 1 hour with undiluted primary 
monoclonal antibodies (MoAbs) of known spedfidty as shown in Table I. The 
sections were then rinsed 3 times for 3 min each in PBS containing 0.2% (WIV) 
glycine in order to remove the unreacted primary MoAb. Subsequently, the 
sections were incubated for 20 min with PBS containing normal goat serum 
followed by a further 1 hour incubation with 10 nm collodial gold-labeled goat-
anti mouse antiserum (GAM 10, Auroprobe EM, Janssen life science products, 
Tilburg, The Netherlands). Excess GAM 10 was removed by 3 rinses of 3 min 
each with PBS containing 0.2% (WIV) glydne, followed by 3 rinses of 1 min 
each with distilled water. Sections were positively stained by a 10 minute 
incubation with uranyl acetate (pH 4.0). Grids were subsequently floated on a 
1.5% methyl cellulose solution for a few seconds and scooped up on wire loops 
of diameter 3-3.5 mm. Access fluid was then removed using a fllter paper until 
gold to blue interference colours developed on the grids. The sections were air-
dried and examined in a Zeiss 901 electron microscope operated at 80 KV. 
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Control sections were treated with rabbit anti-human albumin followed by 
the 10 run GAM-gold probe or by the GAM-gold probe only. Background 
labeling was negligible. Areas of sections showing dark gold grain deposits 
were regarded as positive for cytokeratins. 
The background labeling was very low and was similar to that in the controls 
in which the omission of the primary antibody resulted in the presence of 
sporadic or no gold grains. 
Table I. Source and specificity of the five monoclonal antibodies. 
Monoclonal 
antibody 
RCK 105 
RPN 1166 
Cam 5.2 
RKSE 60 
Ks 19.1 
RESULTS 
Spedfidty Manufacturer 
Anti-cytokeratin 7 Gift, Dr. F.C.S. Ramaekers. 
Anti-cytokeratin 8 Amersham International PLC, Bucks, England, U.K. 
Anti-cytokeratins 8, 18 and 19 Becton-Dickinson, Amersfoort, The Netherlands. 
Anti-cytokeratin 10 Euro-Diagnostics, Apeldoorn, The Netherlands. 
Anti-cytokeratin 19 ICN-Biomedicals Ltd., Bucks, England, U.K. 
The 8 basal cell carcinomas (BCC) that were evaluated comprised 5 solid, 1 
superficial, 1 adenoid and 1 morphea type. The results of the immunoelectron 
microscopy are summarized in Table II. It can be seen that MoAb Ks 19.1 
reacted with the intermediate filaments in the tumor cells and in the normal 
epidermal keratinocytes. An identical number of immunogold grains were 
observed in both cases, indicating the expression of cytokeratin 19 (Figures 1 
and 2). 
A weak reaction was observed with the intermediate filaments in the tumor 
cells and in the normal epidermal keratinocytes using MoAb Cam 5.2 (Figure 3). 
A considerable number of immunogold grains were observed only on the 
intermediate filaments in the tumor cells of the superficial type BCC. 
No reaction at all was observed either in the tumor cells or in the normal 
epidermal keratinocytes in any of the 8 BCC using MoAb RCK 105 and MoAb 
RPN 1166, indicating the lack of expression of cytokeratins 7 and 8 respectively. 
A strong reaction was observed with the intermediate filaments in the normal 
epidermal keratinocytes, and espedally with those in the upper cell layer using 
MoAb RKSE 60, indicating the expression of cytokeratin 10 (Figure 4). No 
reaction was obserVed with this MoAb either in the tumor cells or the basal 
cells of the epidermis in any of the 8 BCC that were examined (Figure 5). 
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Figure 1. Ultracryotomy section of epidermal keratinocyte labeled for cytokera-
tin 19. Intense immunogold labeling near the cell membrane is obseroed 
(x60,000). 
Figure 2. Ultracryotomy section of basal cell carcinoma labeled for cytokeratin 
19. There is an intense immunogold labeling (x 60,000). 
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Figure 3. Ultracryotomy section of epidermal keratinocyte labeled for cyto-
keratins 8, 18 and 19. A weak immunogold labeling of coarse bundles of 
filaments is present (x 52,000). 
Figure 4. Ultracryotomy section of epidermal keratinocyte and comeocyte 
labeled for cytokeratin 10. A selective intense immunogold' labeling is 
observed in the coarse bundles of filaments and of the amorphous 
material of stratum corneum (x 60, 000). 
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Figure 5. Ultracryotomy section of basal cell carcinoma labeled for cytokeratin 
10. Sporadic gold grains are present in the tumor cell (x 60, 000). 
DISCUSSION 
Recently, we reported on the expression of cytokeratins 7 and 19 in basal 
cell carcinoma (BCC) using an indirect immunoperoxidase technique (8). In that 
study the expression of these cytokeratins was inconsistent between and within 
various tumor nests of any particular BCC. Furthermore, cytokeratin 8 was not 
expressed in any of the 21 BCC that were examined. In that study, MoAb Ks 
19.1 reacted with cytokeratin 19 in the tumor cells but did not react with 
cytokeratins in the epidermal keratinocytes. In the present study, gold grains 
were observed on the intermediate filaments in the tumor cells and those of the 
epidermal keratinocytes using MoAb Ks 19.1. In normal skin, used as control, 
cytokeratin 19 was also expressed. When the MoAb Ks 19.1 was diluted, a 
reduction in the reactivity with the intermediate ftlaments in both epidermal 
keratinocytes and in tumor cells was observed. Although a similar reactivity 
pattern was observed using MoAb Cam 5.2, the intensity of labeling was lower 
in most BCC. 
A possible explanation for the discrepancy in the observations concerning 
the expression of cytokeratin 19 in our previous study (8) and this study may 
be that cytokeratin 19 which may be present in a low amount in the epidermal 
keratinocytes reacts weakly with MoAb Ks 19.1. This weak reactivity can only 
be observed after it has been amplified in immunoelectron microscopy. It is 
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also possible, but highly unlikely, that MoAb Ks 19.1 cross-reacted with 
structures other than cytokeratins in the epidermal keratinocytes, since this 
MoAb is claimed by the manufacturer to react exclusively with cytokeratin 19. 
In any case, our present observation need to be confirmed using other 
commerdally available specific anti-cytokeratin 19 monoclonal antibodies. 
It has been reported that low molecular weight cytokeratins which are 
characteristic of simple epithelia are not expressed in stratified epithelia (1). 
However, various low molecular weight cytokeratins have been demonstrated 
in different squamous cell carcinomas derived from stratified epithelia using 
biochemical techniques (12). limited amounts of cytokeratin 8 have also been 
demonstrated biochemically in some BCC (5). However, in the present study, 
the expression of cytokeratin 8 was not observed in any of the 8 BCC that were 
examined, confirming our earlier observations (8). 
1he intermediate filaments in the suprabasal keratinocytes were labeled 
using MoAb RKSE 60, indicating the expression of cytokeratin 10. No gold 
grains were observed on the intermediate filaments either in the epidermal 
basal cells or in the tumor cells. 1hese observations conftrm the observations of 
previous biochemical and immunohistochemical studies (1, 8). 
We did not observe gold grains on the intermediate filaments of the tumor 
cells or the keratinocytes in any of the 8 BCC using MoAb RCK 105. 1his 
demonstrated that cytokeratin 7 was not expressed and is in contrast to our 
previous observations of the light microscopy study in which cytokeratin 7 was 
expressed in 9 of the 21 (43%) BCC that were examined (8). At present we do 
not have a satisfactory explanation for this discrepancy. It has been previously 
reported that fixation procedures may lead to a loss of antigenidty (13). It is 
possible that the ftxation procedure that was used in the present study may 
have decreased the antigenidty of the cytokeratin, thereby redudng its afftnity 
for MoAb RCK 105. 
It has been suggested that the use of other ftxation methods, such as ftxation 
in gluteraldehyde and embedding the tissue samples in epoxy resins, also leads 
to a loss of reactivity (14). The preservation of antigenidty in human epidermis 
has been demonstrated using the Lowicryl K4M protein A-gold method (15, 16). 
In our hands, this method was found to be unsuitable for investigating the 
expression of different cytokeratins in BCC (unpublished observations). 
In summary, the results presented here show that cytokeratin 19 was 
expressed in the tumor cells and the epidermal keratinocytes. However, this 
observation must be conflfllled before any firm conclusions concerning the 
expression of cytokeratin 19 in BCC can be drawn. Cytokeratin 10 was 
expressed only in the differentiated epidermal keratinocytes. The expression of 
cytokeratin 7 in BCC could not be conf1rmed in this immunoelectron 
microscopic study, but the lack of expression of cytokeratin 8 m BCC was 
conf1rmed, eliminating its possible role as a specific histopathological marker. 
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ABSTRACT 
We investigated the peritumoral inflammatory infiltrate in 22 basal cell 
carcinoma (BCC) from 18 patients using a series of monoclonal antibodies. In 
all the 22 BCC the infiltrate consisted mainly ofT cells (55±15%) and only in 
three cases an invasion of the tumor nests by these cells was observed. The T 
helper cr H) subset predominated over the T suppressor/ cytotoxic (Ts;c) subset 
(TH/Ts/c ratio of 1.9±0.8). In 8 of 22 BCC mild infiltrate was observed with 
48±13% T cells and a TH/Ts;c ratio of 1.5±0.6.In 14 of 22 BCC moderate to 
heavy infiltrate with 59±15% T cells and a TH/Ts;c ratio of 2.0±1.0 was 
observed. There was a significant difference in the percentage of T cells in BCC 
with moderate to heavy infiltrate and that in BCC with mild infiltration. The 
mean percentage of HLA-DR+ cells was 54±11%; Langerhans cells (LC) 4±5%; 
and Leu-5+ (monocytes and macrophages) 16±11%. Less than 2% Leu-14+ (B) 
cells were seen in the infiltrate. The mean percentage of Leu-J+ (natural killer) 
cells was 4±4%, and only 1 of 22 BCC Leu-J+ cells invaded tumor nests, 
contacting with tumor cells. From these results we concluded that T cells play a 
major role in the defence against BCC proliferation. The main role of 
Langerhans cells and Leu-M5+ cells may be that of antigen presentation. B cells 
and NK cells probably play a minor role in the local defence against BCC 
proliferation. 
Abbreviations: 
APC: antigen-presenting cell 
BCC: basal cell carcinoma 
IL: interleukin 
LC: Langerhans cells 
MHC: major histocompatibility complex 
MoAb: monoclonal antibody 
NK cells: natural killer cells 
PBS: phosphate-buffered saline 
T H cells: T helper cells 
Ts/c cells:T suppressor/cytotoxic cells 
H&E: haemotoxylin and eosin 
INTRODUCTION 
Basal cell carcinoma (BCC) is the most common tumor of epithelial origin, 
although metastasis fortunately is rare [1,2]. In most cases BCC are slowly 
growing tumors with less tendency of local invasiveness. However, a small 
proportion of BCC showing the histological picture characteristic of aggressive 
growth pattern often leads to local destruction [2,3]. In the last decade several 
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studies have been reported in which attempts have been made to elucidate the 
function of the inflammatory cellular infiltrate surrounding BCC and their 
possible role in the control of tumor growth [4-9]. Dellon et al [4] observed a 
mild lymphocytic infiltrate in situ and a low T cell level in the peripheral blood 
in BCC of large size (>2cm) and an invasive growth pattern. Several authors 
observed that the cellular infiltrate in BCC consisted mainly of T cells [6-8]. Also 
a considerable number of immunoglobulin-bearing cells in the infiltrate 
surrounding BCC have been demonstrated [5,71. Using theE-rosette test and the 
EAC-rosette test, Viae et al [6] observed a T/B ratio of 4.6 in the infiltrated cells 
eluted from BCC. Recently Synkowsky et al [9], using a panel of monoclonal 
antibodies (MoAbs), observed a T/B ratio of 1.0 in situ. These results may 
suggest a significant role of the humoral response in BCC. However, in an 
earlier study Eaglestein et al [8] reported that the infiltrate in BCC consisted of 
90% T cells and less than 10% B cells, which suggested a predominantly T cell-
mediated immune response. 
It is well known that natural killer (NK) cells are important in the defence 
against tumors [10,11]. little is known about the presence and the role of these 
cells in cutaneous tumors. Recently Kohchiyama et al [12] reported on NK cells 
in squamous cell carcinoma of the skin. They observed NK cells in contact with 
carcinoma cells. These authors suggested that NK cells played an important role 
in the defence against squamous cell carcinoma, whereas their role in BCC is 
not clear as yet. To obtain further insight into the composition of the immune 
infiltrate in BCC, and their role especially in tumor defence, we characterized 
the immunoinftltrate in surgically excised BCC using a panel of MoAbs. 
MATERIAlS AND METIIODS 
Twenty-two specimens of BCC were obtained by surgical exClslOn from 
eighteen patients aged 31 to 89 years. The diagnosis of BCC was confmned by 
examining haematoxylin and eosin (H&E) - stained frozen sections and stained 
paraffin embedded sections. The BCC were classified in the conventional 
manner as described previously [2,13]. For histopathological examination of the 
tumor and the skin adjacent to the tumor, the samples were cut lengthwise into 
two equal parts. One portion and the edges of the other portion were fixed in 
formalin and embedded in paraffin for histological confrrmation of diagnosis 
and for determination of tumor-free margins. The remaining portion was frozen 
in liquid nitrogen- cooled isopentane and stored in liquid nitrogen. Serial 
cryostat sections (5 11m in thickness) were placed on alcohol-cleaned glass 
slides, air-dried, and fixed in acetone for 10 min at room temperature and 
stained for the indirect immunoperoxidase (liP) procedure a~ described 
elsewhere [14]. Briefly, the cryostat sections were preincubated with bovine 
serum albumin at a dilution of 1:20 in phosphate-buffered saline (PBS, pH 7.4), 
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for 30 min. The sections were then incubated with an optimal dilution of Leu-
2a, Leu-3a, Leu-4, Leu-6, Leu-7 (HNIG), Leu-14, anti-HLA-DR, or Leu-MS 
(Becton and Dickinson) for 60 min, rinsed in PBS, and incubated with rabbit 
peroxidase-conjugated anti-mouse IgG at an optimal dilution. The perixodase 
reaction was developed by incubating the sections in a mixture of 3,3'-
diaminobenzidine (DAB) at a concentration of 0.5 mg/rnl and hydrogen 
peroxide (0.01%) for 10 min at room temperature. Sections were then rinsed in 
PBS, counterstained with haematoxylin for 1 min, and rinsed again in tap water. 
The sections were mounted in Malinol (Chroma-Gesellschaft, Stuttgart, Federal 
Republic of Germany). 
The specifity of MoAbs Leu-7 (NK cells) and Leu-14 (B cells) was verified 
using frozen tissue sections of human lymph nodes. The negative controls 
comprised the omission of primary antibody and the omission of rabbit anti-
mouse immunoglobulin. 
The amount of mononuclear infiltrate surrounding the tumor nests was 
classified into mild, moderate, and heavy. In most cases the infiltrate was 
examined at three sites. These were the superior (between tumor nests and 
epidermis), lateral, and inferior border of the tumor .. For each antibody the 
percentage of positive staining cells in the infiltrate was estimated by counting 
200 mononuclear cells at x400 magnification. Only the cells showing membrane 
staining were counted. For each antibody identical locations in the serial 
sections were examined. For statistical analysis of the results the Wilcoxon rank 
sum test was used. A P value <0.05 was considered statistically significant. 
RESULTS 
The results are summarized in Table I. The 22 BCC we examined comprised 
9 solid, 6 infiltrating, 3 superficial, 1 morphea, 1 basosquamous, 1 adenoid, and 
1 keratotic type; 10 of the 22 (45%) were smaller than 1 em in size, 8 (36%) 
between 1 and 2 em, and 4 (18%) larger than 2 em (3 of which belonged to the 
superficial type). In 8 of the 22 (36%) we observed a mild infiltrate, a moderate 
infiltrate in 11 (50%), and a heavy infiltrate in 3 (14%). Seven out of 22 BCC 
(32%) showed ulceration, of which 4 BCC had moderate infiltration, 2 mild, and 
l heavy infiltration. The infiltrate was predominantly situated at the tumor's 
lateral and inferior border. In 17 of 22 (77%), either no or only a mild infiltrate 
was observed between the epidermis and the tumor, and only sporadic 
infiltration was observed between the different tumor nests. In cases in which 
either no or only a mild infiltrate was observed at the superior border, and in 
which a moderate or a heavy infiltrate was observed at the other borders, the 
results from the superior border were excluded from calculation of the mean 
infiltrate value. All 3 BCC showing a heavy infiltrate were smaller than 1 em and 
demonstrated a histological picture characteristic of an aggressive growth 
pattern. 
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Immunoinfiltration in basal cell carcinoma 
The mean immunoinfiltration in the 22 BCC consisted of 55±15% Leu-4+ 
(pan T) cells, 49±13% Leu-3a+ (TH) cells, 30±11% Leu-2a+ (T51c) cells, 4±5% 
Leu-6+ cells (LC), 4±4% Leu-7+ (NK) cells, 1±2% Leu-14+(B) Cells, 54±11% 
HLA-DR+ cells, and 16±11% Leu-M5+ (monocytes/macrophages) cells. In 3 BCC 
(cases 4, 11, and 22), some tumor nests had been invaded by TH and Ts;c cells. 
In only 1 of the BCC (case 12) had Leu-r cells invaded tumor nests, moving 
into contact with tumor cells. Leu-6+ and HLA-DR+ cells with a dendritic 
appearance were sporadically observed in tumor nests. In none of the 22 BCC 
were HLA-DR+ tumor cells or HLA-DR+ epidermal keratinocytes seen. In the 
single basosquamous type BCC (case 22), many HLA-DR+ and Leu-6+ cells were 
observed at the periphery of the tumor nests dose to T cells. In all 22 BCC few 
Leu-14+ (B) cells were observed in the infiltrate. No B cells were observed in 
any tumor nest. 
There was no statistically significant correlation between the different 
histological types of BCC and the degree or the composition of the cellular 
infiltrate. There was also no correlation between either the size of the tumors or 
the presence of ulceration and the degree and composition of the infiltrate. It 
can be seen in Table II that, as a group, the BCC with moderate-to-heavy 
infiltrate differed in the composition of their immunocompetent cells from the 
composition found in those BCC with mild infiltrate. The percentage of Leu-4+ 
(PanT) cells was significantly higher in the first group (590/o) than in the latter 
(48%). There was no significant difference between TH cells, Ts;c cells, TH/Tsic 
ratio, LC, NK cells, B cells, HLA-DR+ cells, and monocytes/macrophages in 
these two groups of BCC. 
DISCUSSION 
The results show that the cellular infiltrate in the 22 BCC examined consists 
predominantly of T cells (55±15%). These results agree with those of other 
studies [5-8,15]. In studies using a panel of MoAbs for examining the cellular 
infiltrate in BCC, Synkowski et al [9] found 50o/o-75% T cells with a TH/Ts;c ratio 
of 1.0, while Ernst et al [16] observed 75% T cells with a TH/Ts;c ratio of 1.4. In 
most cases (20 of 22), we observed that in the infiltrate the T H subset exceeded 
the Ts;c subset (mean TH/Ts;c ratio 1.9±0.8). Eaglstein et al [8] also reported a 
larger proportion ofT helper/inducer cells with a TH!Ts;c ratio of 2.2, although 
more than 90% pan T cells were observed. This variation in the results between 
the different studies can be explained on the basis of the use of semi-
quantitative methods, the sensitivity of the immunohistochemical technique, 
and the use of MoAbs obtained from different manufacturers. However, 
Synkowski et al [9] observed no difference in the composition of the cellular 
infiltrate using the same MoAbs (OKT-sera and Leu-sera) simultaneously. 
In the group of BCC with moderate-to-heavy infiltrate, the mean percentage 
of T cells was significantly increased compared to the mean percentage of T 
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cells in BCC with mild infiltration. Although statistically not significant, the T H 
subset and the TH/Ts;c ratio in the first group showed a tendency to increase 
compared to the latter group. Usually most of the infiltrate was localized at the 
lateral and inferior border of the tumor. Since there was no dense infiltrate 
adjacent to the epidermis and no inflammatory cells invaded the epidermis, it 
can be assumed that the concentration of lymphokines and y-interferon in the 
epidermis was too low for initiating the production of class II antigens on 
keratinocytes. In the present study, class II antigens were also not detected on 
the tumor cells in any of the 22 BCC. In cases in which the peritumoral infiltrate 
was heavy, it is possible that although enough lymphokines may be present, 
the tumor cells were unable to produce class II antigens. Since BCC are very 
slow growing tumors that remain localized, it is not likely that T cells are 
activated anywhere but the skin. A decrease in the expression of J32-
microglobulin and class I antigens in BCC has also been reported [17-19]. Since 
the expression of MHC class I or class II antigens on the membrane of the 
antigen-presenting cell (APC) is necessary for the activation of cytotoxic T cells, 
or of T helper cells, respectively, it is conceivable that tumor cells may secrete 
IL-l or other chemotactic factors, which may lead to a nonspecific activation of 
T cells in the peri tumoral infiltrate. In only 3 BCC did cells of the T H and T s;c 
subsets invade some tumor nests, where they appear in contact with tumor 
cells, which suggests a specific T cell-mediated defence against BCC 
proliferation. It is well known that a part of Leu-2a+ cells can act as cytotoxic 
cells [20,21]. The cytolytic capadty ofT helper cells has also been reported [22-
24]. Cell-mediated immune killing was also implicated in BCC showing 
spontaneous regression [25]. Recently Greenway et al [26] reported complete 
cure in eight patients with primary BCC who were treated with recombinant 
alpha-2 interferon. Biopsy examination 2 months after treatment showed no 
tumor cells, but mononuclear infiltration was present. Based on these two 
studies [25,26J, one may speculate on the existence of a cell-mediated immune 
killing that leads to tumor regression. 
In most tumor nests, we observed LC only sporadically, whereas in the 
surrounding infiltrate the mean percentage was 4±5%. There was no correlation 
between the number of LC and the number of T cells. Recently Smolle et al [27] 
reported that the number of LC does not influence the extent of the antitumor 
immune response. The cells of macrophage/monocyte lineage can kill tumor 
cells nonspecifically, induce killing via antitumor antibodies, or can act as an 
APC or indirectly stimulate neoplastic proliferation by secreting growth factors 
[28]. We observed 16±11% Leu-M5+ cells in the infiltrate. It is conceivable that 
LC and a proportion of the monocytes/macrophages in the infiltrate surroun-
ding the BCC bind tumor products that may induce T cell activation by release 
of interleukin-1 (IL-l). The activated T cells will cause proliferation .ofT cells by 
the release of IL-2. 
We observed less than 2% B cells in the infiltrate. A similar outcome was also 
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obtained in 10 BCC using MoAb Leu-12, which reacts with B cells exhibiting 
kappa or lambda light chains. Eaglstein et al [8] and Ernst et al [16] reported less 
than 10% B cells in BCC. However, it cannot be excluded that the MoAbs used 
to identify B cells do not detect all B cells in the infiltrate, espedally mature B 
cells or plasma cells. In the H&E sections of the 22 examined BCC the 
percentage of plasma cells ranged from 0% to 10%. Several authors have 
previously demonstrated a considerable number of immunoglobulin bearing 
cells in the cellular infiltrate surrounding BCC [5-7l. Synkowski et al [9] reported 
that 50%-70% of the cellular infiltrate surrounding BCC consisted of B cells 
identified by MoAb Leu-10. Both these authors [9] as well as the manufacturer 
(Becton and Dickinson) mentioned that Leu-10 has a low specilidty (reacts also 
with monocytes, macrophages, and T cells). Nevertheless, Synkowski et al [9] 
concluded that humoral immunity may play an important role in controlling 
BCC proliferation. In our study, the low percentage of B cells would suggest a 
limited production of antitumor antibodies. However, these antibodies were not 
measured. In addition, a systemic production of anti-BCC antibodies cannot be 
totally excluded. 
NK cells, probably a subpopulation of lymphoid cells, are histologically 
equal to large granular lymphocytes, and considered to be the frrst line of 
defence against tumors [10,11]. Most Leu-r (NK) cells lack T cell markers; 
however, a small proportion of NK cells can express these markers [29,30]. NK 
cells have been observed in squamous cell carcinoma, follicular lymphoma, 
Hodgkin's lymphoma, and hepatocellular cardnoma, where they frequently 
appeared in contact with tumor cells [12,31,32]. We observed 4±4% Leu-r cells 
in the cellular infiltrate surrounding BCC. In only 1 of 22 BCC (case 12) 15% 
Leu-r cells were observed, and some NK cells had invaded the tumor nests. 
No NK cells were observed either invading or in the tumor nests of the other 21 
BCC. This would plead for a minimal role of NK cells in the defence against 
BCC proliferation. Similar observations have been made in BCC in a study dted 
in the footnote by Kohchiyarna et al [12]. 
In conclusion, the results of this immunohistological study suggest a 
predominantly T cell-mediated immune response, with a minor participation of 
NK cells and B cells in defence against BCC. For further understanding of the 
exact function of T cells, the number of activated T cells exhibiting IL-2 
receptor (anti-Tac) and the subclassification of the T helper subset in helper 
inducer and helper suppressor (4B4 and 2H4) will be of much value and is 
currently being investigated. 
ACKNOWLEDGEMENTS 
The authors thank Miss E. Buitenhuis and Miss I. Vonk of the Department of 
Pathology for their excellent technical assistance, Dr. S.J.M. Wijthoff of the 
Department of Plastic and Recontructive Surgery for providing the tumor 
samples, and Miss L. v.d. Heuvel for typing this manuscript. 
69 
Chapter 5 
REFERENCES 
1 Pollack SV, Goslen ]B, Sherertz EF, Jegasothy BV: The biology of basal cell 
carcinoma: a review. J Am Acad Dermatol 7: 569-577, 1982 
2 McGibbon DH: Malignant epidermal tumors. J Cutan Pathol 12: 224-238, 
1985 
3 Lang PG, Maize JC: Histologic evolution of recurrent basal cell carcinoma 
and treatment implications. J Am Acad Dermatol 14: 186-196, 1986 
4 Dellon AL, Potvin C, Chretien PB, Rogentine CN: The immunobiology of 
skin cancer. Plastic and Reconstructive Surgery 55: 341-354, 1975 
5 Bustamante R, Schmitt D, Pillet C, Thivolet J: Immunoglobulin-producing 
cells in the inflammatory infiltrates of cutaneous tumors. Immunocytologic 
identification in situ. J Invest Dermatol 68: 346-349, 1977 
6 Viae J, Bustamante R, Thivolet J: Characterization of mononuclear cells in 
the inflammatory infiltrates of cutaneous tumors. Br J Dermatol 97: 1-10, 
1977 
7 De Panfilis G, Colli V, Manfredi G, Mish I, Rima S, Zampetti M, Allegra F: In 
situ identification of mononuclear cells infiltrating cutaneous carcinoma: an 
immuno-histochemical study. Acta Derm Venereol (Stockholm) 59: 219-222, 
1979 
8 Eaglstein NF, Hernandez AD, Allen II JE: Lymphocytic response to basal-
cell carcinoma: in situ identification of functional subsets using monoclonal 
antibodies. J Dermatol Surg Oncol 8: 943-947, 1982 
9 Synkowski DR, Schuster P, Orlando JC: The immunobiology of basal cell 
carcinoma: an in situ monoclonal antibody study. Br J Dermatol 113: 441-
446, 1985 
10 Herberman RB, Holden HT: Natural killer cells as antitumor effector cells. J 
Natl Cancer Inst 62: 441-445, 1979 
11 Herberman RB, Ortaldo JR: Natural killer cells: their role in defences against 
disease. Science (Wash DC) 214: 24-30, 1981 
12 Kohchiyama A, Oka D, Ueki H: Immunohistologic studies of squamous cell 
carcinoma: possible participation of Leu-r (natural killer) cells as antitumor 
effector cells. J Invest Dermatol 87: 515-518, 1986 
13 Lever WF, Schaumburg-Lever G: Histopathology of the Skin: Basal Cell 
Epithelioma. 6th ed. Philadelphia, JP Lippincott Co., 1983, pp 562-575 
14 Lansdorp PM, van der Kwast Th, de Boer M, Zeylemaker WP: Stepwise 
amplified immunope~oxidase (PAP) staining. I. Cellular morphology in 
relation to membrane markers. J Histochem Cytochem 32: 172-178, 1984 
15 Claudy AL, Viae J, Schmitt D, Alasio A, Thivolet J: Identification of 
mononuclear cells infiltrating basal cell carcinomas. Acta Derm Venereol 
(Stockh) 56: 361-365, 1976 . 
16 Ernst T-M, Muller-Mai C: Immunphanothypisierung und Morphometrie des 
entzundlichen Infiltrates Basaliomvarianten. Tagungsberich der 116. 
70 
Immunoinflitration in basal cell carcinoma 
Wissenschaftliche Tagung der Vereinigung Rheinisch-Westfalischer 
Dermatologen. Bochum, 1986, pp 663 
17 Tjernlund UM, Forsum U: Beta-2-microglobulin in basal cell carcinoma. 
Acta Derm Venereal (Stockh) 57: 503-506, 1977 
18 Turbitt ML, MacKie RM: Loss of 132-microglobulin from the cell surface of 
cutaneous malignant and premalignant lesions. Br J Dermatol 104: 507-513, 
1981 
19 Hua LA, Kagen CN, Carpenter RJ, Goltz RW: HLA and l3z-microglobulin 
expression in basal and squamous cell carcinomas of the skin. Int J 
Dermatol 24: 660-663, 1985 
20 Roitt I, Brostoff ], Male D: Immunology: Cell-mediated Immunity. 
Edinburgh, Churchill Uvingstone Gower Medical Publishing, London, 1985, 
Chap. 11, pp 1-8 
21 Shimizu K, Shen F-W: Role of different T cell sets in the rejection of 
syngeneic chemically induced tumors. J Immunol122: 1162-1165, 1979 
22 Pober JS, Collins T, Michael A, Gimbrone ], Cotran RS, Gitkin ]D, Piers W, 
Clayberger C, Krensky AM, Burakoff SJ, Reiss CS: Lymphocytes recognize 
human vascular endothelial and dermal fibroblast 12 antigens induced by 
recombinant immune interferon. Nature (Lond) 305: 726-729, 1983 
23 Wahlin B, Perlmann P: Characterization of human K cells by surface 
antigens and morphology at the single cell level. J Immunol131: 2340-2347, 
1983 
24 Fukuzawa M, Fujiwara H, Yoshioka T, Itoh K, Hamaoha T: Effector cell 
analysis of tumor cell rejection in vivo in two syngeneic tumor systems 
exhibiting distinct in vitro cytotoxic mechanisms. Gann 75: 912-919, 1984 
25 Curson C, Weedon D: Spontaneous regression in basal cell carcinomas. J 
Cutan Pathol6: 432-437, 1979 
26 Greenway HT, Cornell RC, Tanner DJ, Peets E, Bardin GM, Nagi C: 
Treatment of basal cell carcinoma with intralesional interferon. J Am Acad 
Dermatol15: 437-443,1986 
27 Smolle J, Soyer H-P, Ehall R, Bartenstein S, Kerl H: Langerhans cell density 
in epithelial skin tumors correlates with epithelial differentiation but not 
with the peritumoral infiltrates. J Invest Dermatol 87: 477-479, 1986 
28 Mantovani A, Evans R: Tumor-infiltrating leukocytes. Immunology Today 6: 
143-145, 1985 
29 Abo T, Miller CA, Gartland GL, Balch CM: Differentiation stages of human 
natural killer cells in lymphoid tissues from fetal to adult life. J Exp Med 
157: 273-284, 1983 
30 Tilden AB, Abo T, Balch CM: Suppressor cell function of human granular 
lymphocytes identified by the HNK-1 (leu-7) monoclonal antibody. J 
Immunol130: 1171-1175, 1983 
31 Si L, Whiteside TL: Tissue distribution of human NK cells studied with anti-
leu 7 monoclonal antibody. J Immunol130: 2149- 2155, 1983 
71 
Chapter 5 
32 Pizzolo G, Semenzato G, Chilosi M, Morittu L, Ambrosetti A, Warner N, 
Bofill M, Ganossy G: Distribution and heterogeneity of cells detected by 
HNK-1 monoclonal antibody in blood and tissues in normal, reactive and 
neoplastic conditions. Clin Exp Immunol 57: 195-206,1984 
HNK-1 Antigen Is not Specific for Natural Killer Cells* 
To the Editor: 
we read with great interest the article by Habets et al, published in the March 
1988 issue [1]. The peritumoral inflammatory infiltrate of basal cell carcinoma 
(BCC) has been investigated by using a series of monoclonal antibodies. The 
authors provided evidence for a minor participation of natural killer (NK) cells, 
in defense against BCC, on the basis of the low percentage of Leu-7 (HNK-1)-
positive cells in the infiltrate. Unfortunately the HNK-1 antigen, isolated by Abo 
and Balch in 1981 [2], cannot be considered specific for NK cells. Rather, the 
HNK-1 antigen is coexpressed by most CD8-positive/CD11b-positive suppressor 
cells [3]. Indeed, Phillips and Babcock identified a new antigen in 1983 [4], 
named NKP-15 (CD16), considered to be spedfic for essentially all human NK 
cells. A number of fmdings demonstrate that CD16 antigen is specific for NK 
cells, while the HNK-1 antigen is not. First, functional studies from Lanier et al 
[5] and Abo et al [6] have well established that CD16-positive cells display high 
levels of NK activity, while HNK-1-positive/CD16-negative cells possess low 
levels of cytotoxic cell function. On the other hand, CD16-positive/HNK-1-
negative cells, when stimulated with interleukin-2 [7] or with NK-sensitive tumor 
cells K-562 [8], markedly augment their NK cell activity, while stimulated HNK-
1-positive/CD16-negative cells never display higher NK cell function. Moreover, 
CD16-positive cells are able to phagocytize AET-sheep red blood cells (SRBC), 
whereas HNK-1-positive/CD16-negative cells never display phagocytic capabili-
ty for AET-SRBC [9]. As for morphologic characteristics, CD16-positive cells 
show significant ultrastructural differences in comparison to HNK-1-
positive/CD16- negative cells [10,11], as previously demonstrated by using a 
peroxidase-colloidal gold double labeling in immunoelectron microscopy [12]. 
Ultrastructural differences were confirmed by morphometric investigations [13]. 
Finally, a new antigen, named NKH-1 (Leu-19), which is expressed on the 
whole non-major histocompatibility complex-restricted cytotoxic cell 
population, comprising NK cells has recently been described [14,151 
In conclusion, the HNK-1-positive/CD16-negative cell subset seems to be 
distinct from the CD16-positive NK cell population. As a result, 
immunohistochemical studies performed by Werner Habets et al cannot rule out 
the possibility that NK cells play a role in the defense against BCC. This issue 
could be resolved by further investigations dealing with CD16. and NKH-1 
antigens. 
•Letter to the Editor:] Invest Dermatol 91: 374-75, 1988. 
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REPLY. 
The authors acknowledge Dr. Manara's comments regarding our recent 
publication [1]. Indeed, as stated in our article we did not totally exclude the 
participation of leu 7 (HNK-1) positive cells in the defense against basal cell 
carcinoma (BCC). In a recent publication Kohchiyama et al [2], using leu 7 
(HNK-1) monoclonal antibody, also concluded that the cellular cytotoxicity 
mediated by NK cells may not be the main defense against BCC. Although 
HNK-1 antigen may be coexpressed by most leu 2a (CD-8) positive suppressor 
cells, our results showed only 4±4% leu 7 (HNK-1) positive cells, whereas the 
mean percentage of leu 2a (CD-8) positive suppressor cells was 3o±ll %. Thus, 
despite its broader specificity, the leu 7 (HNK-1) antibody fails to react with the 
majority of Leu 2a (CD-8) positive suppressor cells. We agree that CD-16 
antigen is specific for NK cells, but in our recent investigations, using anti-leu 
11b (CD-16) and anti-leu 7 (HNK-1) monoclonal antibodies simultaneously, we 
observed identical percentages of positively reacting cells in the peritumoral 
inflammatory infiltrate in BCC. We intend to extend these studies using both 
these monoclonal antibodies in a double labeling technique in order to verify 
our observations. Further investigations dealing with CD-16 and the newly 
described NKH-1 (Leu-19) antigens would also be useful in elucidating the 
participation of NK cells in the defense against BCC. 
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HLA-DR and (32-microglobulin in basal cell carcinoma 
ABSTRACT 
The expression of human leukocyte antigen-DR (HLA-DR) and 132-microglo-
bulin on the tumor cells and their correlation (if any) to the degree and the 
composition of the peritumoral mononuclear infiltrate were studied in 37 basal 
cell carcinomas (BCC) from 32 patients using an indirect immunoperoxidase 
technique. In 36 out of 37 BCC (97%) there was no expression of HLA-DR of 
tumor cells of BCC. In 13 out of 37 BCC (35%) 132-microglobulin was expressed 
on the tumor cells. In only 6 out of these 13 BCC both a diffuse cytoplasmic as 
well as a membrane staining was observed; in the other 7 BCC only a diffuse 
cytoplasmic staining was observed.In all the 37 BCC there was membrane 
staining for !32-microglobulin in the normal epidermis. The intensity of staining 
in the normal epidermis was always stronger than that in the tumor nests. There 
was a varying degree of peritumoral immune infiltrate in all BCC. It comprised 
mainly ofT cells (mean percentage 57±15). In the group of BCC with moderate 
to heavy infiltrate the mean percentage of T cells was 63±13, which was 
significantly higher than the mean percentage ofT cells (46±14%) in the group 
of BCC with a mild infiltrate. This difference was mainly due to an increase in T 
helper cells. The absence of HLA-DR or the decreased expression of 132-micro-
globulin neither correlated with the degree nor the composition of the 
peritumoral infiltrate. From these results it can be concluded that despite the 
absence of HLA-DR and a decreased expression of 132-microglobulin on tumor 
cells of BCC, a T cell-mediated immune response against BCC proliferation is 
evoked. 
INTRODUCTION 
Basal cell carcinomas (BCC) are the most common cutaneous cancers of 
epithelial origin in humans. A proportion of BCC depending on the specific 
histological features are aggressive in their growth pattern causing local 
destruction that leads to mutilation and recurrence after surgery (1-3). There is a 
varying degree of mononuclear cell infiltration in BCC. Several studies have 
been undertaken to eluddate the function of the peritumoral mononuclear 
infiltrate and its possible role in the control of tumor growth (4-9). In our recent 
study (10), it was demonstrated that the peritumoral infiltrate in BCC consisted 
mainly of T cells, suggesting a predominantly T cell-mediated immune response 
in these tumors. As to the role of T cells, it is as yet uncertain whether they are 
specifically or non-specifically activated against tumor cells (10). For a 
specifically activated T cell-mediated immune response against tumor cells, it is 
necessary that class I and class II antigens of the major histocompatibility 
complex (MHC) be expressed on tumor cells (ll). An absence of 132-
microglobulin and HLA class I antigens in BCC has been reported (12-16), but 
in three of these studies (12, 15, 16), !32-microglobulin and HLA-ABC were 
expressed to a varying degree in a proportion of the BCC. Little is known 
concerning the expression of class II antigens (HLA-DR) on tumor cells in BCC. 
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The aim of our study was to investigate the expression of (32-microglobulin 
and HLA-DR on tumor cells of BCC and whether their expression had any 
influence on the degree and the composition of the peritumoral inflammatory 
infiltrate. Our results fail to support those reported recently in this journal by 
Kohchiyama et al (17) who observed the expression of HLA-DR in 5 out of 8 
BCC. In the present study, HLA-DR was not expressed on the tumor cells in 36 
out of 37 BCC that were examined. There was a weak expression of HLA-DR in 
the remaining BCC. 
METHODS 
Samples 
Thirty-seven specimens of basal cell carcinoma (BCC) were excised from 32 
patients aged 31 to 89 years (mean 63 years). The diagnoses of BCC were 
confirmed by examination of haematoxylin and eosin (H&E)-stained frozen 
sections and stained paraffm-embedded sections. 
The BCC were classilled in the conventional manner as described previously 
(2,18). For the histopathological examination of the tumor and the skin adjacent 
to it, the samples were cut lengthwise into two equal parts. One portion and 
the edges of the other portion were fued in formalin and paraffin-embedded 
for histological confirmation of the diagnosis and for determination of tumor-
free margins. The remaining portion was frozen in liquid nitrogen-cooled 
isopentane and stored in liquid nitrogen. 
Indirect immunopero:xidase test (liP) 
Serial cryostat sections, 5 Jlm thick, were placed on alcohol-cleaned glass 
slides, air-dried, fixed in acetone for 10 min at room temperature, and stained 
using the procedure described in our previous studies (10,19). Briefly, the 
cryostat sections were preincubated with bovin serum albumin at a dilution of 
1:20 in phosphate-buffered saline (PBS, pH 7.4) for 30 min. The sections were 
then incubated with an optimal dilution of one of the monoclonal antibodies 
Leu-4, Leu-3a, Leu-2a, anti-HLA-DR or (32-microglobulin (Becton and Dickinson) 
for 60 min, rinsed in PBS and incubated with rabbit peroxidase-conjugated anti-
mouse IgG (Dakopatts, _Amsterdam) at a dilution of 1:50. The peroxidase 
reaction was developed by incubating the sections with 3,3'-diaminobenzidine 
(Sigma chemical Co., St. Louis, MO) at a concentration of 0.5 mg/ml and 0.01% 
hydrogen peroxide for 10 min at room temperature. Sections were then rinsed 
in tap water, counterstained with haematoxylin for 1 to 2 min and rinsed again 
in tap water. The sections were mounted in Malinol (Chroma-Gesellschaft, 
Stuttgart). The negative controls comprised either the omission of primary 
antibody or rabbit anti-mouse immunoglobulin. 
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The peritumoral mononuclear infiltrate was graded as mild, moderate, or 
heavy as reported previously (10). For each antibody the percentage of positive 
staining cells in the infiltrate was determined by counting 200 mononuclear 
cells at x400 magnification. The number of tumor cells that stained for HLA-DR 
or ~2-microglobulin was estimated in the whole section and expressed as a 
percentage. For statistical analysis of the results the Wilcoxon rank sum test was 
used. A p value of< 0.05 was considered as statistically significant. 
RESULTS 
The 37 BCC we examined comprised 16 solid, 3 superfidal, 3 adenoid, 1 
keratotic, 1 cystic, 9 infiltrating, 2 morphoeic and 2 basosquamous types. The 
latter 3 have histological features that are characteristic of an agressive growth 
pattern. The tumor size of the 37 BCC ranged from 0.4 to 4 em and 13 of them 
showed ulceration. Twenty-seven BCC were located in the face, 3 in the neck, 6 
on the trunk and 1 on the arm. There was no correlation between the size of 
the BCC, the presence of ulceration or the aggressiveness and the degree or the 
composition of the peritumoral infiltrate. 
In none of the 36 BCC HLA-DR was expressed on tumor cells. In the 
remaining basosquamous type BCC with a heavy peritumoral infiltrate, the 
tumor cells showed a weak membrane staining for HLA-DR. In 5 of 37 BCC, it 
was observed that Leu-4+ (pan 1) cells and HLA-DR+ cells invaded some tumor 
nests and were in close contact with the tumor cells. However, in these cases 
HLA-DR was not expressed on the tumor cells. An example of the reactivity 
pattern of MoAb HLA-DR is shown in Figure 1. In all BCC HLA-DR+ cells with a 
dendritic appearance were sporadically observed in tumor nests. In 35 of 37 
BCC, keratinocytes in the normal epidermis did not express HLA-DR. However, 
in the remaining 2 cases with a heavy infiltrate between the tumor nests and the 
epidermis, the epidermis was focally stained. In 13 of 37 BCC (35%) ~z­
microglobulin was expressed on the tumor cells. The estimated percentage of 
positively stained tumor cells ranged from 5% to 80% (mean 60%). Seven of the 
13 positively stained tumors only showed a diffuse cytoplasmic staining, 
whereas the other 6 BCC showed both a membrane as well as a diffuse 
cytoplasmic staining. An example of the latter staining pattern is shown in 
Figure 2. In all BCC, the intensity of the staining in the normal epidermis was 
stronger than that in the tumor cells. The keratinocytes in the normal epidermis 
only showed a membrane staining. There was no correlation between the 
expression of ~z-microglobulin in BCC and the histological type of BCC or the 
degree of peritumoral immune infiltrate as shown in Table I. However, it was 
striking that 4 of 6 BCC that showed a diffuse cytoplasmic as well as a 
membrane staining for ~z-microglobulin were of the infiltrating type BCC. 
In 14 of 37 BCC (38%) a mild peritumoral infiltrate was observed, and in 23 
of 37 BCC (62%) a moderate to heavy infiltrate was observed. It can be seen in 
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Figures la and lb: Cryostat section (5 Jlm) of solid type BCC showing a heavy 
HIA-DJ?+ peritumoral infiltrate (arrows). Tumor cells do not stain. (MoAb 
HIA-DR, liP technique, x 135 and x 340, respectively.) 
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Figure2: 
Cryostat section (5 
Jlm) of solid type BCC. 
Membrane staining of 
most of the tumor cells 
(arrows).(MoAb f3zmi-
croglobulin, liP-tech-
nique, x 340.) 
HLA-DR and j32-microglobulin in basal cell carcinoma 
Table II, that the mean percentages of T cells and HLA-DW cells in all the 37 
BCC were 57±15 and 57±11, respectively. The mean percentages ofT helper 
cells and T suppressor/cytotoxic cells were 49±14 and 28±13, respectively. The 
mean percentage of T cells in the group of BCC with moderate-to-heavy 
peritumoral infiltrate (63±13%) was significantly higher ( p < 0.01) than in the 
group with mild infiltrate (46±14%). The mean percentage ofT helper cells was 
also significantly higher (p < 0.05) in the group of BCC with moderate-to-heavy 
peritumoral infiltrate (55±12%) than in the group with mild infiltrate 
(43±13%).There was no significant difference in mean percentages of HLA-DR+ 
cells and T suppressor/cytotoxic cells in both groups of BCC. There was also no 
correlation between the expression of J32-microglobulin in BCC and the mean 
percentages ofT cells, T helper cells, T suppressor/cytotoxic cells, or of HLA-
DR+ cells in the peritumoral infiltrate. 
Table L· Expression of [32 -microglobulin in basal cell carcinoma (BCC) and its 
relationship to histological characteristics and degree of peritumoral 
immunoinfiltrate. 
Total numbers of BCC 
Group I 
Group II 
Group III 
Group IV 
Number and percentage of BCC 
expressing 132-microglobulin 
13/37 
9/24 
4/13 
5/14 
8/23 
(35%) 
(37%) 
(31%) 
(36%) 
(35%) 
Group I = BCC showing benign histological characteristics 
Group II = BCC showing aggressive histological characteristics 
Group III = BCC with mild peritumoral infiltrate 
Group IV = BCC with moderate-to-heavy peritumoral infiltrate 
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HLA-DR and ~2-microglobulin in basal cell carcinoma 
DISCUSSION 
The results of this study show that the tumor cells of basal cell carcinomas 
(BCC) do not express HLA-DR antigens. Several studies reporting the 
peritumoral infiltrate in BCC have been published (9, 20-22). In those studies 
monoclonal antibodies against HLA-DR were also used. In none of those 
studies did the authors report on the expression of HLA-DR on tumor cells in 
BCC. However, Natali et al (15, 23), using 2 different monoclonal antibodies 
observed the expression of HLA-DR on tumor cells in 1 of 13 BCC in one study 
(15) and in 2 of 3 BCC in a separate study (23). Furthermore, Kohchiyama et al 
(17) recently reported in this journal on the expression of HLA-DR in BCC. 
They observed the expression of HLA-DR on tumor cells in 5 of 8 BCC. The 
tumor cells located at the periphery of the tumor nests were predominantly 
stained with monoclonal antibody (MoAb) OKial. However, as shown in their 
article, the intensity of staining of the tumor cells for HLA-DR was weak 
especially as compared to the intensity of staining of the peritumoral 
mononuclear infiltrate cells. Moreover, in our experience, it is rather difficult to 
distinguish between the infiltrating cells and the tumor cells which are HLA-DR 
positive in those BCC in which the mononuclear inflammatory cells invaded 
the tumor nests. The possible explanations for the contradictions between their 
results and the results of the present study may be due to the use of different 
immunohistological techniques, the use of monoclonal antibodies obtained 
from different manufactures and the differences in the interpretation of the 
staining patterns. 
In the present study, ~2-microglobulin was not expressed in 24 of the 37 
(65%) BCC that were examined. In the other 13 (35%) ~2-microglobulin was 
expressed. However, in these cases the mean percentage of stained tumor cells 
was 60% (range 5% to 80%), but the intensity of staining was always lower than 
that of the normal epidermis in the same cryostat section. In 6 of these 13 BCC, 
in addition to a diffuse cytoplasmic staining, a membrane staining of the tumor 
cells was also observed. Both the total absence of ~2-microglobulin on tumor 
cells and the lower intensity of staining are indicative of a decreased expression 
of ~z-microglobulin in BCC. These results are in agreement with the results of 
other studies (12,15,16). 
There have been several conflicting reports regarding the expression of the 
heavy chain of the major histocompatibility complex (MHC), class I antigens in 
BCC (14-16, 24). Mauduit et al (14) observed that in BCC the HLA-heavy chain 
molecule was expressed without the expression of HLA-light chain (~2-micro­
globulin). However, other authors reported both an absence and a reduction in 
the intensity of staining for HLA-ABC and for ~z-microglobulin in most BCC 
(15,16,24). An absence of class I antigens in malignant tumors of other tissues 
such as breast, colon, lung, endothelium has been observed (25). It is well 
known that expression of class I antigens on tumors is necessary for associative 
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recognition of tumor antigens by cytotoxic T cells (11). However, in the present 
study, there was no correlation between the expression of 132-rnicroglobulin on 
the tumor cells and the mean percentage of Leu 4+ cells, the mean percentage 
of Leu 3a+ cells, the mean percentage of Leu 2a+ cells, or the mean percentage 
of HLA-DR+ cells in the peritumoral infiltrate, including the T cells invading the 
tumor nests. This is similar to the observations in a breast cancer study in which 
such a correlation could not be established (25). In contrast to these 
observations in melanoma and in melanocytic nevi, the degree of mononuclear 
inflammatory infiltrate was correlated to the expression of class I antigens on 
these tumor cells (26). In the present study we observed that an increase of 
peritumoral mononuclear infiltration cells was caused by an increase of T cells. 
This increase was mainly due to an increase in T helper cells. Although, class II 
antigens were not expressed on the tumor cells of BCC, there was an increase 
in T helper cells. Specific activation of T helper cells against tumor antigens on 
rumor cells can only occur in associative expression of class II antigens. 
Therefore, it is conceivable that tumor products binding to antigen-presenting 
cells such as Langerhans cells and macrophages, which were present in the 
peritumoral infiltrate as observed in our previous study (10), could evoke a 
specific T cell-mediated response. Alternatively, non-specific activation of T 
cells by interleukin-1 and other chemotactic factors secreted by tumor cells 
cannot be totally excluded. 
In conclusion, the results presented here suggest that although the tumor 
cells of BCC do not express HLA-DR and in a majority of cases do not express 
l3z-rnicroglobulin, the presence and the degree of peritumoral immunoinfiltrate 
are not affected. Moreover, a T cell-mediated immune response against BCC 
proliferation is not influenced. 
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Immunoinflitration in Bowen's Disease 
ABSTRACT 
We investigated the dermal inflammatory infiltrate and the expression of 
HLA-DR and (32-microglobulin on the tumor cells in 8 Bowen's disease (BD) 
using a series of monoclonal antibodies. The inflammatory infiltrate was classi-
fied as mild, moderate or heavy. The infiltrate in all cases consisted mainly of T 
cells (55±21 %) and where the T helper (T H) subset predominated over the T 
suppressor/cytotoxic (T81c) subset (TH/Ts;c ratio of 2.4±1.0). The mean percen-
tage of HLA-DR positive cells was 58±18%, Langerhans cells (LC) 4±1% and 
Leu-M5 positive cells (monocytes/macrophages) 9±2%. The mean percentage of 
B cells and natural killer (NK) cells was 4±5% and 1±2% respectively. B cells 
and NK cells did not invade any of the tumors. In the 5 BD with moderate or 
heavy infiltrate, TH cells, Ts;c cells and Leu-M5 positive cells did invade the 
tumor. In the tumor area where there was invasion, the number of LC was 
increased and HLA-DR was expressed on the tumor cells. 132-microglobulin was 
generally expressed on the tumor cells of BD. We concluded that there is 
evidence for a T cell-mediated anti-tumor immune response which may account 
for the infrequent invasive growth in BD. 
INTRODUCTION 
Bowen's disease (BD) is an uncommon intraepithelial cancer of the skin. 
Inorganic arsenic and exposure to sun light are considered as possible etiologi-
cal factors. Although invasive growth is rare, at least 5% of the lesions are 
known to invade the underlying dermis (Maize et al. 1979). In these cases, 
more than one third of the patients will develop metastasis. In contrast to BD, 
solar keratosis in which 10% to 15% of the lesions develop into invading 
squamous cell carcinoma, no metastasis has been observed (Graham et al. 
1%6). 
In most BD, a moderate amount of mononuclear inflammatory infiltrate is 
observed in the upper dermis (Lever et al. 1983).1t has been reported that the 
inflammatory infiltrate in other types of skin neoplasia such as basal cell 
carcinomas, squamous cell carcinomas and melanoma consists mainly ofT cells 
(Eaglstein et al. 1982; Ruiter et al. 1982; Kohchiyama et al. 1986; Ralfkiaer et al. 
1987; Habets et al. 1988). We recently reported (Habets et al. 1988) that the 
defence against basal cell carcinomas is predominantly T cell-mediated with 
minor participation of NK cells and B cells. In contrast to basal cell carcinomas, 
in squamous cell carcinomas not only T cells but also B cells and NK cells seem 
to play a role in the local defence (Kohchiyama et al. 1986). To date, the 
inflammatory infiltrate in BD has not been characterized. Since only about 5% 
of the BD will invade the dermis it would be interesting to know whether the 
inflammatory infiltrate plays a role in any defence against invasive growth. To 
obtain insight into the composition of this inflammatory infiltrate and its role in 
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tumor defence, we typed this infiltrate and investigated the expression of !3r 
microglobulin and HLA-DR on the tumor cells. 
MATERIALS AND METIIODS 
Six 4 mm biopsy specimens and 2 surgically excised specimens of BD were 
obtained from 5 patients aged 42-74 years. The location of the 8 BD that were 
examined was as follows. Three were located in the head and neck region, 2 
were located on the arms and 3 were located in the trunk region. For 
histological examination of the tumor, the samples were cut in two equal parts. 
One part was fixed in formalin and paraffin embedded. The diagnosis of BD 
was confirmed by examining haematoxylin and eosin (H&E)-stained sections. 
The remaining part was frozen in liquid nitrogen-cooled isopentane and stored 
in liquid nitrogen. Three serial cryostat sections (5 !liD in thickness) were placed 
on each alcohol-cleaned glass slide, air dried and frx:ed in acetone for 10 min at 
room temperature and stained using the indirect immunoperoxidase (liP) 
procedure described in our previous study (Habets et al. 1988). Briefly, the 
cryostat sections were preincubated with 5% ( w /v) bovine serum albumin in 
phosphate- buffered saline (PBS, pH 7.4) for 30 min. The sections were then 
incubated with an optimal dilution of the monoclonal antibody (MoAb) Leu-2a 
forT suppressor/cytotoxic (T81c;) cells, Leu-3a forT helper (TH) subset, Leu-4 
for all T cells (pan T), Leu-6 for Langerhans cells (LC), Leu-7 (HNK1) for natural 
killer (NK) cells, Leu-14 for B cells, Leu-M5 for monocytes/macrophages, anti-
HLA-DR and anti-!32-microglobulin (Becton & Dickinson) for 60 min, rinsed in 
PBS and incubated with rabbit peroxidase- conjugated anti-mouse IgG or in the 
case of Leu-7 with rabbit peroxidase conjugated anti-mouse IgM at an optimal 
dilution. The peroxidase reaction was developed by incubating the sections 
with 3,3'-diaminobenzidine (DAB) at a concentration of 0.5 mg/ml and 
hydrogen peroxide (0.01%) for 10 min at room temperature. Sections were then 
rinsed in PBS, counterstained with haematoxylin for 1 min and rinsed again in 
tap water. The sections were mounted in Malinol (Chroma-Gesellschaft, 
Stuttgart). 
The specillcity of MoAbs Leu-7 and Leu-14 was verified using frozen tissue 
sections of human lymph nodes. The negative controls comprised the use of an 
irrevelant MoAb, the omission of primary antibody and the omission of rabbit 
anti-mouse immunoglobulin. 
The criteria for the classillcation of the dermal mononuclear inilltrate were 
based on the estimation of the total number of infiltrating cells. In each case the 
infiltrate was examined in 3 serial sections on the same glass slide. Depending 
on the total number of infiltrating cells in each case, the infiltrate was graded as 
mild (a low number), as heavy (a high number) and as moderate when the total 
number of infiltrating cells was between the other two categories. For each 
monoclonal antibody the percentage of stained cells in the infiltrate was 
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estimated by counting 200 mononuclear cells at x400 magnification. Only the 
cells showing membrane staining were counted. For each antibody identical 
locations in the serial sections were examined. 
RESULTS 
The composition of the inflammatory infiltrate is summarized in Table I. In 3 
of the 8 BD, we observed a mild inflammatory infiltrate, a moderate infiltrate in 
3 and a heavy infiltrate in 2. In th_e latter 5 BD, mononuclear infiltrate was also 
observed in the lower part of the tumor. The mean composition of the infiltrate 
in 8 BD was 55±21% Leu-4 positive (pan T) cells, 5o±19% Leu-3a positive (T H) 
cells, 23±11% Leu-2a positive (Ts;C> cells, 4±1% Leu-6 positive cells (LC), 1±2% 
Leu-7 positive (NK) cells, 4±5% Leu-14 positive (B) cells, 9±2% Leu- M5 positive 
cells (monocytes/macrophages) and 58±18% HLA-DR positive cells. The TH/Ts;c 
ratio was 2.5±1.0. The composition of the mononuclear cells that invaded the 
tumor is shown forT cells (Fig. 1), TH and Ts;c cells (Fig. 2) and macrophages 
(Fig. 3). No B cells or NK cells were observed in the tumors. In the 5 cases with 
moderate and heavy infiltrate there was an increase in LC in the lower part of 
the tumor in the region where the T cells and macrophages invaded the tumor 
(Fig. 4) as compared to the marginal epidermis. In addition in that area, the 
tumor cells expressed HLA-DR (Fig. 5). 
[32-microglobulin was expressed on the tumor cells of all the 8 BD. However, 
in 3 cases (cases 5, 6 and 8) groups of tumor cells were either stained very 
weakly or not at all, but the tumor cells which were in contact with the 
immunocompetent cells present in the lower part of the BD were always 
stained. 
Table!: 
Summary of phenotypes of Infiltration and expression off3z-Mtcroglobulin (/3z-MG) and HLA-
DR on tumor cells tn 8 Bowen~ Disease. 
Case Degree of I.eu-4 I.eu-3a Leu-2a Tufl".;c I.eu-6 I.eu-7 I.eu-14 l.eu-M5 HIA-DR Expression on tumor cells 
infiltration Jlz-MG HIA-DR 
1. mild 20 20 5 4.0 5 0 0 5 25 + 
2. mild 40 40 10 4.0 5 1 0 5 40 + 
3. mild 50 40 20 2.0 2 1 0 10 75 + 
4.• moderate 80 60 30 2.0 5 1 4 10 70 + (+) 
s.• moderate 40 35 25 1.4 5 1 7 10 60 + (+) 
6.• moderate 60 70 35 2.0 3 0 ·2 8 60 + (+) 
7." heavy 80 70 35 2.0 5 5 15 10 60 + (+) 
8." heavy 70 65 25 2.6 2 1 3 10 76 + (+) 
Mean±S.D. 55±2150±19 23±112.5±1.0 4±1 1±2 4±5 9±2 58±18 
1he results represent the mean estimated percentage of cells stained in the upper dermis. 
• = Invasion of tumor by immunocompetent cells 
+ = Membrane staining of tumor cells 
( +) = Membrane staining of tumor cells in the lower part of the 
tumor close to the dense dermal infiltrate. 
- = No staining 
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Figure 1: 
Cryostat section (5J.Lm) 
of Bowen's Disease 
showing a heavy 
dermal infiltrate with 
more than 75% Leu-4 
positive (pan T) cells. 
MoAb Leu-4, liP 
technique, x55. T cells 
invade the tumor 
(arrows) 
Figure2: 
Cryostat section (5J.Lm) 
of Bowen's Disease 
showing Leu-2a posi-
tive cells (suppressor/ 
cytotoxic T cells) 
invading the tumor 
and in contact with 
tumor cells. MoAb Leu-
2a, liP technique, 
x340. 
Immunoinfiltration in Bowen's Disease 
Figure] 
Cryostat section 
(5J1m) of Bowen's 
Disease showing 
Leu-M5 positive 
cells ( monocytesl-
macrophages) in 
the infiltrate. A 
jew stained cells 
are seen invading 
and in contact 
with the tumor 
cells (arrow). 
MoAb Leu-M5, liP 
technique, x]40. 
Figure4: 
Cryostat section 
(5 Jl.m) of Bowen's 
Disease showing 
an accumulation 
of Leu-6 positive 
cells (Langerhans 
cells) in the lower 
part of the tumor. 
MoAb Leu-6, liP 
technique, x135. 
Note the dense 
dermal infiltrate 
(asterisk). 
Figure 5: Cryostat section (5 Jl.m) of 
Bowen's Disease showing HLA-DR 
positive tumor cells (arrows). HLA-DR 
positive infiltrate cells are seen both in 
the dermal infiltrate and in the tumor. 
MoAb anti-HLA-DR, liP technique, x 
340. 
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DISCUSSION 
The results show that the inflammatory infiltrate in BD consisted predomi-
nantly of T cells (55±21 %). This corroborates the results of the infiltration 
studies in other skin tumors (Eaglstein et al. 1982; Ruiter et al. 1982; 
Kohchiyama et al. 1986; Ralfkiaer et al. 1987; Habets et al 1988). In all the BD 
we examined, the T H subset predominated the Ts;c subset (mean T H/T s;c ratio 
of 2.4±1.0). In basal cell carcinomas the TH subset also predominates the Ts;c 
subset (Eaglstein et al. 1982; Habets et al. 1988), whereas in melanomas the TH 
subset generally equals the Ts;c subset (Poppema et al. 1983; Ralfkiaer et al. 
1987). In squamous cell carcinomas the TH/Ts;c ratio is reversed in favour of 
the Ts;c subset (Kohchiyama et al. 1986). 
In the 5 BD (cases 4-8) with moderate or heavy infiltrate, T H as well as Ts;c 
cells invaded the tumor and were observed to be in contact with the tumor 
cells. At the site of invasion, the tumor cells were observed to be HLA-DR 
positive and the number of Langerhans cells (LC) in the same area was 
increased as compared to the rest of the tumor. In the remaining 3 BD (cases 1-
3) with a mild infiltrate, the tumor was not invaded either by THor by Ts;c cells 
and HLA-DR was not observed on the tumor cells. This suggests that the 
expression of HLA-DR in BD may be dependent on whether or not there is an 
invasion of the tumor by T cells. However, a larger number of patients must be 
investigated to confirm this observation. The expression of HLA-DR on the 
tumor cells has been observed in melanoma (Ruiter et al. 1982; Brocker et al. 
1984) and colorectal cancer (Daar et al. 1983). In both these types of tumors, 
there was no correlation between the degree of mononuclear infiltrate and the 
expression of HLA-DR on the tumor cells. In basal cell carcinomas and 
squamous cell carcinomas HLA-DR was not expressed on the tumor cells 
(Kohchiyama et al. 1986; Habets et al. 1988, 1989). In a recent study by 
Kohchiyama et al. (1987), HLA-DR was expressed by basal cell carcinoma but 
these results have not yet been confirmed. The results of our recent study 
(Habets et al. 1989) contradict their fmdings. In the present study ~2-micro­
globulin was expressed on the tumor cells of all BD, but in three cases there 
were also groups of tumor cells that either stained weakly or not at all. A total 
or a partial absence of ~rmicroglobulin on the tumor cells in BD has been 
reported (Turbitt et al. 1981; Mauduit et al. 1983; Hua et al. 1985). 
In those BD where the major histocompatibility complex (MHC) class I and 
class II antigens are expressed on the tumor cells, activation of TH and Ts;c 
subsets may occur leading to a T cell-mediated anti-tumor response. The tumor 
antigens presented in conjunction with HLA-DR will be recognized by TH cells. 
Subsequently, activation and proliferation ofT cells occur by release of lympho-
kines (interleukin-1, interleukin-2 and interferon-gamma). Since HLA-DR positive 
tumor cells were not observed in BD with a mild inflammatory infiltrate, it 
seems unlikely that the expression of HLA-DR on the tumor cells preceeds the 
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activation and proliferation of the immune infiltrate. In the BD with a moderate 
or heavy infiltrate, we observed an accumulution of LC in the lower part of the 
tumor close to the dense dermal infiltrate. Since not only activated T cells but 
also LC may produce interferon-gamma (Knop et al. 1988), it is likely that the 
production of interferon-gamma is high enough to induce HLA- DR expression 
on the tumor cells. 
The anti-tumor activity of macrophages may consist of non- specific killing of 
tumor cells, killing of tumor cells byanti-tumor antibodies via antibody-
dependent cell-mediated cytotoxicity (ADCC) or even act as antigen-presenting 
cells (APC) for tumor antigens (Mantovani et al. 1985; Hamilton et al. 1987). We 
observed 9±2% Leu-M5 positive cells some of which invaded the tumor. Upon 
closer careful examination of the sections, HLA-DR positive large non-dendritic 
cells were observed indicating the presence of activated macrophages in contact 
with the tumor cells. These observations suggest that macrophages act as anti-
tumor effector cells. 
We observed 4% B cells in the infiltrate. However, in 2 of the 8 BD (cases 5 
and 7) we observed 7% and 15% B cells which suggest a possible local produc-
tion of anti-tumor antibodies. Since in these cases activated macrophages were 
observed in contact with the tumor cells, it is possible that tumor killing via 
ADCC may also occur. Kohchiyarna et al. (1986) reported that in most 
squamous cell carcinomas, a considerable number of B cells were present 
which suggested that B cells played a role in the local anti-tumor response. In 
other cutaneous tumors such as basal cell carcinomas (Eaglstein et al. 1982; 
Habets et al. 1988) and melanomas (Ruiter et al. 1982; Ralfkiaer et al. 1987), the 
number of B cells in the infiltrate was very limited, indicating a minor role of B 
cells. 
NK cells are considered to be the flrst line of defence against tumors 
(Herberman et al. 1979, 1981). In the present as well as our previous study on 
basal cell carcinoma (Habets et al. 1988), a minimal number of NK cells were 
observed. This suggested a limited role of NK cells in the local defence against 
these tumors. A low number of NK cells have also been reported in melanoma 
(Ralfkiaer et al. 1987). Since the number of NK cells in most tumors in situ is 
limited, it has been proposed that their main role may be that of eliminating 
micro-metastases (Vose et al. 1985). 
In conclusion, our results support a T cell-mediated anti-tumor response in 
BD in which the Langerhans cells and the cells of macrophage/monocyte 
lineage also play a supportive role. B cells and NK cells seem to play a minor 
role or no role at all in the local defence against BD. This predominantly T cell-
mediated immune response may at least in a proportion of BD be directly or 
indirectly responsible for the low incidence of the development of BD into 
invasive carcinoma. 
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Treatment of basal cell carcinoma with interferon 
ABSTRACT 
In this pilot trial, the efficacy of low dose human recombinant interferon 
gamma (riFN-y) as an outpatient therapy was investigated in 7 patients. Each 
patient had a biopsy-confirmed basal cell carcinoma (BCC) of the nodular type. 
Each BCC was injected intralesionally twice weekly for 4 weeks (8 total 
injections) with 2x105 IU (0.1 ml) of riFN-y per injection (total dose 1.6x106 IU). 
All patients were evaluated for tumor response and toxicity with a follow-up of 
8 weeks after the completion of the therapy. Clinical responses measured 
during therapy showed that although there was a flattening of the lesions in all 
cases, there was no reduction in the size of the lesions in any case. 
Histopathological examination of the biopsies obtained 8 weeks after the 
completion of the therapy confirmed the presence of tumor in all cases. This 
demonstrated that low-dose intralesional therapy had no antitumor effect. The 
therapy was safe and was well tolerated with minimal toxic effects by all 
patients. The lack of antitumor effect in the present pilot trial may be due to the 
low-dose that was used but is in contrast to the successful intralesional therapy 
of BCC with recombinant alpha-2 interferon. 
INTRODUCTION 
Basal cell carcinomas (BCC) are the most common cutaneous cancers of 
epithelial origin in man. Fortunately, metastases are extremely rare (1). 
However, a proportion of BCC depending on the specific histological features 
are aggressive in their growth pattern causing local destruction which leads to 
mutilation and recurrence after surgery (2). Various clinical and histologic forms 
of basal cell carcinoma include the nodular-ulcerative, superficial, pigmented, 
morphea-like and fibroepitheliomatous types (3). 
The current treatment methods include excision, cryosurgery, irradiation, and 
currettage and electrodesiccation with high cure rates of around 95o/o ( 4). Some 
primary BCC depending on their location and histopathology and recurrent 
BCC may respond best to Mohs' surgery. Cure rates via Mohs' surgery approach 
990/o for all primary BCC and 96o/o to 98o/o for recurrent BCC (5). However, all 
the above mentioned therapies, especially irradiation can cause undesirable side 
effects. Although the cure rates of BCC using surgical techniques are high, non-
surgical approaches to BCC therapy in selected cases is not only desirable but 
may offer advantages especially in cases of multiple BCC, recurrent BCC and 
BCC that are difficult to operate due to their location. 
In recent years, much attention has been focused on interferons as promising 
therapeutic agents in the treatment of skin diseases (7). To date, several clinical 
studies have been reported in which intralesional administration of interferon-a 
resulted in the successful treatment of various skin diseases such as BCC (6,8), 
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actinic keratoses (9), and condylomata acuminata (10). Interferon-y has been 
used to treat patients with lepromatous leprosy (11). 
Although, interferon-y is a well-characterized macrophage-activating factor 
and a potent immune-modulating agent, its physiologic function and therapeu-
tic potential are as yet undefined in patients with BCC. Since there was no 
previous experience in using recombinant interferon gamma (riFN-y) for the 
treatment of BCC, a conservative approach similar to that used previously to 
treat lepromatous leprosy patients was chosen (11). The main objectives of the 
investigations described in this pilot clinical study were to determine the 
efficacy of twice weekly intralesional treatment with low-dose riFN-y in 
outpatients with histologically confirmed primary BCC of the nodular type and 
to assess whether riFN-y administered according to this treatment regimen was 
safe and well tolerated (minimal side effects). 
MATERIALS AND METIIODS 
Patients 
Two female and 5 male patients aged 55-75 years (mean 64 years), each with 
a biopsy-confirmed primary basal cell carcinoma (BCC) of the nodular type 
took part in this pilot trial. The size of the BCC varied form 6x8 mm to 14x22 
mm and were located as follows: forehead/temporal region(3), leg (1), ear (1), 
eyebrow (1) and cheek (1). Four mm punch biopsies were taken prior to the 
start of the therapy and the diagnosis of BCC was confirmed by 
histopathological examination of haematoxylin and eosin (H&E)- stained 
sections. All patients were healthy and their lesion which was to be injected 
was considered treatable by an alternative therapy. None of the patients had 
received radio-, chemo-, or immunotherapy prior to riFN-y therapy. Patients 
were aware of their diagnosis and all available therapies but chose to receive 
riFN-y as an outpatient therapy. All patients underwent a complete history and 
thorough physical examination before the start of the therapy. The lesion which 
was to be treated was measured, photographed and its location documented. 
All patients were informed on the nature of the pilot trial, its possible hazards 
and of their right to withdraw at any time from the study without prejudice and 
without jeopardy to their future medical treatment. They all agreed to cooperate 
in all aspects of the trial and provided informed written consent. 
Laboratory tests 
Pretherapy tests included a total blood count with differential white blood 
cell count, complete physical examination (including body weight, performance 
status and vital signs), a chemistry profile including liver and renal function 
tests and a urine analysis. The entire haematology and chemistry tests were 
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repeated 2 weeks and 4 weeks after the start of the therapy. A complete 
physical examination was repeated 8 weeks after the therapy was completed. 
Treatment 
All patients were treated on an outpatient basis at the department of 
Dermato-Venereology, academic hospital Dijkzigt, Erasmus University, Rot-
terdam. They were treated with the human recombinant interferon gamma 
(riFN--y) supplied as a sterile lyophilized powder (specific activity: 2x107 IU/mg 
protein) in 0.5 mg vials by Boehringer Ingelheim b.v., Alkmaar, The 
Netherlands. The vials were stored at 2°-8° C. Each 0.5 mg vial was 
reconstituted with 1 ml sterile water. This solution (concentration 0.5 mg/ml) 
was diluted 5 fold with sterile physiological saline to correspond to 10 J.Lg (0.1 
ml) dose of riFN-y. Reconstitution was accomplished by gentle inversion of the 
vial and each vial was used only once. Each lesion was injected with 0.1 ml 
(2x105 IU) riFN-y via a 30-gauge needle on a tuberculin syringe. The needle 
was inserted tangentially into the center of the lesion assuring that the content 
of the syringe was delivered intralesionally. This was repeated twice weekly 
(Mondays and Thursdays) for 4 weeks. Each lesion was injected with a total of 
1.6x106 IU (2x105 IU x 8 doses). During therapy, the patients were evaluated 
for therapeutic response and toxic side effects at weekly intervals for 4 weeks 
and one and two months after the therapy was completed. 
Therapeutic response criteria 
The following criteria were used to evaluate the degree of therapeutic 
response. Clinical healing of all lesions was regarded as complete response. A 
partial response was defmed as a 50% or greater reduction in the size (product 
of perpendicular diameters) of the lesion. No response was defined as no 
change in the lesion qualifying as a partial response or disease progression. An 
increase of 25% or greater in the size of the lesion was considered as 
progressive disease. 
Therapeutic responses were measured during the therapy and follow-up by 
evaluating the size and flattening of the lesion. Four mm punch biopsies were 
taken from each lesion before, after and 8 weeks after the completion of the 
therapy.Histological confirmation for the presence of the tumor was obtained 
by examining haematoxylin and eosin (H&E)-stained paraffm embedded 
sections. 
RESULTS 
The particulars of the seven patients are summarized in Table I. Clinical 
responses measured during therapy showed that although there was a flattening 
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Table I. Tbe characteristics of the seven patients. 
Patient Age Sex TypeofBCC Location of BCC Pretreatment lesion Posttreatment lesion 
No. (yr) size(=) size (mm) 
Oweek 8weeks 
1. 55 M Nodular Forehead/temporal 12x 13 14 X 15 11 X 13 
75 
region 
2. F Nodular Leg 6x8 6x8 4x9 
3. 56 F Nodular Eyebrow 6x8 5x8 4x7 
4. 63 M Nodular a Cheek 11 X 17 8x 14 9 X 18 
5. 70 M Nodular Forehead/temporal 14x22 16x 24 16 X 22 
6. 72 M Nodular 
region 
Forehead/temporal 7x 12 13 X 15 12 X 15 
60 
region 
7. M Nodular Ear 7x9 8x8 8x9 
autceration present 
During the therapy a flattening of all lesions was observed. Tumor present in all 
follow-up excisional biopsies. 
All tumors were excised 8 weeks after the completion of the therapy. 
of the lesions in all seven cases, there was no reduction in the size of the 
lesions in any case. An example of the nodular basal cell carcinoma lesion 
before, after and 8 weeks after the completion of the therapy is shown in 
Figures 1, 2 and 3 respectively. 
Histopathological examination of the biopsies taken from the lesions 8 weeks 
after the completion of the therapy confirmed the presence of tumor in all 
cases. An example of such a lesion before and 8 weeks after the completion of 
the therapy is shown in Figures 4 and 5 respectively. In Figure 5 it can be seen 
that there is an increase in the degree of peritumoral inflammatory infiltrate 
after the therapy. 
A summary of the toxic side effects is depicted in Table II. Fatigue and slight 
fever were observed in patients 2, 3 and 4 after the first injection. After the 
second injection, patient 2 had a slight fever and headache whereas patient 3 
had only a slight fever. No toxic side effects were observed in patients 1, 5, 6 
and 7. All the toxic effects were mild and transient and all the 7 patients were 
able to complete the therapy. 
No laboratory abnormalities were observed in the haematological profile, 
liver and renal function tests or urine analysis in any patient during or after 4 
weeks of the therapy. A complete physical examination of all patients 8 weeks 
after the completion of the therapy showed them to be in good health. 
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Figure 1: 
Nodular basal cell 
carcinoma lesion in 
the eyebrow region of 
patient 3 before 
therapy. 
Figure2: 
Nodular basal cell 
carcinoma lesion in 
the eyebrow region of 
patient 3 after 
receiving 8 interferon 
injections. 
Figure3: 
Nodular basal cell 
carcinoma lesion in 
the eyebrow region of 
patient 3 after a 
follow-up of 8 weeks 
posttreatment. 
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Figure4: 
Photomicrograph of pretreatment biopsy 
specimen showing nodular basal cell 
carcinoma. (Hematoxylin-eosin stain; 
x60). 
Figure 5: Photomicrograph of biopsy 
specimen of the same nodular basal 
cell carcinoma after a follow-up of 8 
weeks posttreatment. Note the dense 
peritumoral inflammatory infiltrate 
(arrows). (Hematoxylin-eosin stain; 
x60). 
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Tabel II. Toxic side effects during treatmentfl 
Patient no. 1 2 3 4 5 6 7 Total 
Fever (after flrst dose) + + + 3 
Fever (after other doses) + 1 
Malaise 0 
Itching (at site) 0 
Light headedness 0 
Pain (at site) 0 
Headache + 1 
Fatigue + + + 3 
Perspiration + 1 
Muscle aches 0 
Chills 0 
aAU the toxic effects were mild and transient. 
DISCUSSION 
The therapeutical potential of human recombinant interferon gamma (riFN-y) 
has received considerable attention. It is only recently that human riFN-y has 
become available in sufficient quantities to evaluate its use as an anticancer 
agent. A number of clinical studies have recently been reported in which riFN-y 
was used as an anticancer agent to treat patients with malignant solid tumors 
(12, 13, 14), rheumatoid arthritis (15) and skin diseases such as psoriasis (16, 
17) and lepromatous leprosy (11). No clinical studies have been reported on the 
use of riFN-y in basal cell carcinoma (BCC). Recently, Greenway et al (6) 
evaluated the effectiveness of intralesionally injected alpha-2 interferon in 8 
patients with BCC. Their results showed that the therapy led to the complete 
cure of BCC and had mild side effects. 
In the pilot clinical trial reported here, the clinical efficacy of low-dose riFN-y 
therapy was evaluated in seven patients with biopsy-confirmed nodular type 
BCC. Since no guidelines were available for the treatment of BCC with riFN-y, 
a conservative approach was adopted. The choice of dose and the route of 
riFN-y administration were aimed at minimizing the dose-related toxic side 
effects and were similar to those used in a previous study by Nathan and 
coworkers to treat 6 patients with lepromatous leprosy (11). In the present 
study, each patient received a total of 1.6x106 IU riFN-y administered 
intralesionally on an outpatient basis. 
The results of this pilot trial clearly showed that intralesional therapy with 
low-dose riFN-y was ineffective. No antitumor effect was observed since there 
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was no reducqon in the size of the lesions during or after the completion of the 
therapy. However, a flattening of the lesions was noted in all 7 patients during 
the therapy. The presence of tumor was also conf1rmed by histopathological 
examination of biopsies taken 8 weeks after the completion of the therapy. 
The clinical ineffectiveness of riFN-y therapy reported here is in marked 
contrast to the highly effective alpha-2 interferon therapy reported by Greenway 
et al (6). In their study, although the type of BCC (superficial or nodular) and 
the route of administration (intralesional) of alpha-2 interferon were identical to 
that of the present study, a much higher dose (about 8 fold) of alpha-2 
interferon was used. However, this marked difference in the total dose used in 
the two studies does not explain the opposite therapeutic effects on the same 
type of BCC. It is noteworthy, that although the low-dose riFN-y that was used 
in the present study showed no antitumor effect did show immunomodulatory 
effects (Tank et al. manuscript in preparation). 
It is also possible that the low-dose which was used for therapy in the 
present study was insufficient to boost the natural killer (NK) cell activity, to 
induce the release of interleukin-2 required forT cell activation, and to induce 
the expression of the major histocompatibility complex class II (HLA-DR) 
antigens on the tumor cells of BCC. Normally, the tumor cells of BCC do not 
express HLA-DR antigens (18). The expression of HLA-DR antigens is essential 
for a specific T cell-mediated antitumor immune response (19). However, it was 
recently reported by Schulze et al (16) that riFN-y failed to induce the 
expression of HLA-DR and of ~z-microglobulin in BCC. This may explain the 
observed lack of antitumor effect reported here. 
In psoriasis, the therapeutic effects of recombinant interferons alpha and 
gamma seem to be the reverse of those observed in BCC. Intramuscular 
administration of riFN-y to patients with chronic plaque-type psoriasis resulted 
in a marginal therapeutic effect (17), whereas the administration of interferon 
alpha was reported to cause exacerbation of psoriasis (20). Therefore, it seems 
very likely that the clinical therapeutic effects of recombinant interferons alpha 
and gamma in BCC and psoriasis are inherent to the type of interferon that is 
used for therapy. 
Although the results of this pilot clinical trial failed to demonstrate the 
therapeutic effectiveness of low-dose riFN-y in BCC, the intralesional therapy on 
an outpatient basis was safe and was well tolerated with minimal side effects. 
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General discussion and summary 
Although considerable literature exists on various aspects of basal cell 
carcinoma (BCC), there are controversies concerning the immuno-histopatholo-
gy of BCC which not only exhibit a broad spectrum of clinical manifestations, 
but also of histological appearances. In order to obtain a detailed insight into 
the immuno-histopathology of BCC, two different investigational approaches 
were persued. The investigations described in the first half of this thesis 
(Chapters 2, 3 and 4) were performed in an attempt to investigate whether 
useful tumor markers were present in BCC. The presence of such markers 
would be of value in diagnostic histopathology. The investigations described 
in the second half (Chapters 5, 6 and 7) were mainly focused on the detailed 
characterization of the inflammatory infiltrate in BCC and Bowen's Disease 
(BD) and its role in the defence against these tumors. Investigations into the 
therapeutic efficacy of an immunomodulatory agent in BCC are described in 
Chapter 8. 
The investigations described in Chapter 2 were undertaken using two 
monoclonal antibodies (MoAb) which were observed to react with basal cell 
determinants of normal epidermis. Indirect immunoperoxidase and indirect 
immunofluorescence techniques were used. The results showed that the two 
MoAb reacted with different determinants of the epidermal basal cells and BCC 
tumor cells. Initially, it was believed that one of the Moab had anti- cytokeratin 
activity. However, upon detailed immunoblotting studies it was observed to 
lack this activity. At the same time, a number of specific MoAb against specific 
cytokeratins had become commercially available and it was possible to classify 
and catalogue the distribution of cytokeratins in various dermatological 
diseases. As a result of earlier biochemical studies, Mollet al (1,2) had reported 
that cytokeratin 8 was expressed in some BCC. Therefore, in the studies 
described in Chapter 3, the distribution of the low molecular weight 
cytokeratins 7, 8, 18, 19 and the high molecular weight cytokeratin 10 were 
investigated in BCC using an indirect immunoperoxidase technique and MoAb 
of specific anti-cytokeratin activity in an attempt to establish whether 
cytokeratin 8 was expressed in BCC and whether it could be a useful 
histopathological marker for these tumors. The results showed that cytokeratins 
7 and 19 were expressed inconsistently between and within various BCC, 
whereas cytokeratin 8 was not expressed in any of the BCC that were 
examined. In order to resolve the discrepancy between the observations of the 
immuno-histological and biochemical studies, immunoelectron microscopic 
investigations described in Chapter 4 were conducted. The results failed to 
confirm the expression of cytokeratin 7 in BCC but the lack of expression of 
cytokeratin 8 was confirmed in BCC excluding its possible role as a useful 
histopathological marker. These results also failed to corroborate the results of 
earlier biochemical studies (1,2). 
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Previous studies (3-7) on the characterization of the inflammatory infiltrate 
in BCC were contradictory, especially with regards to its cellular composition 
and the role of humoral immunity. Furthermore, the presence of NK cells in 
BCC was not investigated. The detailed characterization of the immune infiltrate 
in surgically excised BCC is described in Chapter 5. The expression of {3z-
microglobulin and the human leukocyte antigen-DR (HLA-DR) on the tumor 
cells of BCC and their influence on the degree and composition of the 
peritumoral immune infiltrate is described in Chapter 6. The results showed that 
the peritumoral infiltrate consisted predominantly of T cells suggesting that 
these cells played a major role in the defence against BCC. The low number of 
B cells and NK cells in the infiltrate indicated that these either played a minor 
role or no role at all in the defence against BCC. The limited involvement of 
these cells against BCC proliferation was also simultaneously confirmed by 
Kohchiyama et al (8). The absence of HLA-DR and the decreased expression of 
{32-microglobulin on the tumor cells of BCC did not influence the degree or the 
composition of the peritumoral infiltrate. These results also failed to corroborate 
the results reported earlier (8). The composition of the infiltrate in sec differed 
from that observed in BCC (9). In SCC, not only T cells, but also B cells and NK 
cells seem to play a role in the defence against tumor proliferation. However, 
the inflammatory infiltrate in carcinoma in situ, namely Bowen's Disease (BD) 
has not been previously characterized. Since only a low number of carcinoma 
in situ ever invade the dermis, an insight was obtained into whether the inflam-
matory infiltrate played a role in preventing invasive growth and whether its 
composition differed from that observed in BCC and SCC. In the studies 
described in Chapter 7, this infiltrate was characterized and the expression of 
{32-microglobulin and HLA-DR on the tumor cells of BD was investigated. The 
results showed that the infiltrate consisted predominantly of T cells which 
suggested a T cell-mediated anti- tumor response which may be at least in a 
proportion of BD directly or indirectly responsible for the low incidence of the 
development of BD into invasive carcinoma. Langerhans cells and cells of 
macrophage/monocyte lineage also played a supportive role. HLA-DR was 
expressed on tumor cells only in those cases where T cells invaded the tumor. 
However, a larger number of tumors must be evaluated prior to drawing any 
ftrm conclusions. 
In recent years, the therapeutic potential of biological response modifters 
such as interferons has received much attention in cancer (10). The production 
of these agents in adequate amounts via the recombinant-DNA technology has 
permitted their clinical evaluation as anti-cancer drugs. Recently, two studies 
were reported in which human recombinant interferon-alpha 2a (11) and -alpha 
2b (12) were administered intralesionally to patients with BCC. Tl).e results of 
these two clinical trials were contradictory in that interferon-alpha 2a was 
observed to have no anti-tumor effect, whereas interferon-alpha 2b was shown 
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to be effective. Although interferon gamma is a potent immunomodulatory 
agent, its therapeutic potential in BCC had not been investigated. Therefore, the 
pilot clinical study described in Chapter 8 was undertaken. There was no anti-
tumor response in any case after intralesional therapy with low-dose human 
recombinant interferon gamma in BCC. This failure could have been due to the 
low dose that had been used. However, the final assessment concerning the 
therapeutic value of this drug has to await further clinical investigations. 
Concluding remarks 
One of the commonest epithelial cancers in caucasians is BCC. At present it 
is expected that the incidence of BCC will increase in the future and as a result 
the morbidity of this disease in the western population is also expected to 
increase. Considering this aspect, the investigations reported in this thesis 
contribute towards a clearer insight into the immunohistological aspects of BCC 
which may form the basis for further research and may contribute towards the 
development of new effective therapeutic modalities. 
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CHAPTER 10 
Sam en vatting 

Samenvatting 
Het basaalcelcarcinoom (BCC) is de meest frequent voorkomende huidmalig-
niteit bij het blanke ras. Zowel klinisch als histologisch kan het BCC zich op 
verschillende wijzen manifesteren. Hoewel over de diverse aspecten van het 
BCC veel gepubliceerd is, bestaan er ten aanzien van de immuno-histo-
pathologie tegenstrijdige bevindingen. 
Hoofdstuk 1 geeft een inleiding in het onderwerp en een overzicht van de 
diverse aspecten van het BCC. 
Om een gedetailleerd inzicht te krijgen in de immuno-histopathologie van 
het BCC werden twee verschillende onderzoekslijnen gevolgd. In de eerste helft 
van het proefschrift (Hfdst. 2, 3 en 4) wordt het onderzoek beschreven dat tot 
doel had bruikbare tumor markers voor BCC op te sporen. Het gebruik van 
deze markers is van belang voor de diagnostiek in de klinische pathologie. 
In hoofdstuk 2 worden de resultaten beschreven van onderzoek met twee 
monodonale antilichamen die reageren met verschillende determinanten van de 
epidermale basale cellen. Hierbij werd aangetoond dat een van deze mono-
donale antilichamen (MoAb 12G7) reageerde met een membraan gebonden 
determinant van zowel de basale cellen van de normale epidermis als van de 
tumorcellen van het BCC. Het andere monodonale antilichaam (253B7) 
reageerde met een cytoplasmatische determinant van de normale epidermale 
basale cellen en in 15% van de onderzochte BCC met een cytoplasmatische 
determinant van de tumorcellen. Er werd aanvankelijk verondersteld dat de 
cytoplasmatische determinant een cytokeratine was. Met behulp van immuno-
blotting experimenten vertoonde dit monodonale antilichaam echter geen 
anti-cytokeratine activiteit. 
Inmiddels kwamen diverse monoclonale antilichamen met specifieke anti-
cytokeratine activiteit commerdeel beschikbaar, zodat in een volgende studie 
de expressie van de cytokeratines 7, 8, 18 en 19 met een laag moleculair 
gewicht en cytokeratine 10 met een hoog moleculair gewicht in het BCC 
bestudeerd kon worden (Hoofdstuk 3). Met name het onderzoek naar de 
expressie van cytokeratine 8 in het BCC was van belang, daar in het verleden 
uit biochemisch onderzoek is gebleken dat cytokeratine 8 in sommige BCC 
voorkomt. In geen van de 21 onderzochte BCC kwam cytokeratine 8 tot 
expressie; wel werden de cytokeratines 7 en 19 aangetoond. In een daarop-
volgend onderzoek werd met behulp van een immuno-electronen-
microscopische techniek getracht de bestaande discrepantie tussen de 
immunohistologische en biochemische bevindingen op te heffen (Hoofdstuk 4). 
Ook in deze studie kon cytokeratine 8 niet worden aangetoond in BCC. Hieruit 
werd gecondudeerd dat cytokeratine 8 niet kan dienen als een bruikbare 
histopathologische tumor marker voor het BCC. 
De onderzoekingen in de tweede helft van het proefschrift (Hfdst. 5, 6 en 7) 
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hadden tot doel het ontstekingsinfiltraat in het BCC en in het intra-epidermale 
carcinoom (Morbus Bowen) immunohistologisch te typeren en de mogelijke rol 
van dit inflitraat ten aanzien van de tumorafweer te bestuderen. Hoewel in het 
verleden diverse onderzoekingen zijn verricht naar de karakterisering van het 
ontstekingsinflitraat in het BCC, waren de resultaten niet eensluidend, vooral 
niet ten aanzien van de samenstelling van het ontstekingsinfiltraat en de rol van 
de humorale immuniteit. Bovendien was de aanwezigheid van NK-cellen in het 
BCC niet onderzocht. Uit de in hoofdstuk 5 beschreven resultaten blijkt dat het 
ontstekingsinfiltraat in het BCC voornamelijk uit T-cellen bestaat. B-cellen en 
NK-cellen zijn slechts in een gering aantal aanwezig. Hieruit kan geconcludeerd 
worden dat T-cellen een belangrijke rol spelen in de tumorafweer, terwijl de 
rol van B-cellen en NK-cellen waarschijnlijk beperkt is. Verder werd 
aangetoond dat het humaan leucocyten antigeen DR (HLA-DR) niet tot 
expressie komt en dat ~2-microglobuline slechts in een aantal gevallen tot 
expressie komt op de tumorcellen van het BCC (Hoofdstuk 6). Noch de mate 
van het ontstekingsinfiltraat noch de samenstelling van het infiltraat werd 
hierdoor beinvloed. Bij plaveiselcelcarcinomen van de huid blijken behalve T-
cellen ook B-cellen en NK-cellen een rol te spelen in de tumorafweer. Daar 
over de compositie van het ontstekingsinflitraat en zijn rol in de preventie van 
invasieve groei van het intra-epidermale carcinoom (Morbus Bowen) niets 
bekend was, werd het infilraat in deze tumor immunohistologisch getypeerd en 
de expressie van HLA-DR en ~2-microglobuline op tumorcellen onderzocht 
(Hoofdstuk 7). Het infiltraat bestond voornamelijk uit T-cellen. Bij meer dan de 
helft van de onderzochte intra-epidermale carcinomen werd geobserveerd dat 
T-cellen de tumor binnendrongen en dat de tumorcellen positief waren voor 
HLA-DR. Tevens bestond er een toename van Langerhans cellen en macropha-
gen. Deze bevindingen leidden tot de veronderstelling dat de T-cel 
gemedieerde tumorafweer direct of indirect ertoe bijdraagt, dat de overgang 
van het intra-epidermale carcinoom naar een invasief groeiend cardnoom 
wordt voorkomen. Om definitieve conclusies te kunnen trekken dient echter 
een groter aantal tumoren onderzocht te worden. 
De laatste jaren wordt veel aandacht besteed aan de therapeutische waarde 
van zogenaamde "biological response modifiers", zoals interferonen, bij kanker. 
Dankzij de recombinant DNA-techniek kan voldoende van deze stoffen 
geproduceerd worden. Dit heeft o.a. geleid tot klinisch onderzoek bij de 
behandeling van diverse soorten kanker. In hoofdstuk 8 worden de resultaten 
beschreven van een klinische studie naar het effect van humaan recombinant 
interferon-gamma, een potent immuno-modulerend agens, dat intralesionaal in 
een lage dosis toegediend werd bij paW~nten met een BCC. Bij geen van de 
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patienten werd een verbetering waargenomen. Voordat echter een eindoordeel 
kan worden gegeven over de therapeutische waarde van interferon-gamma 
dient er verder klinisch onderzoek verricht te worden. 
De inddentie van het BCC, de meest voorkomende vorm van huidkanker, 
zal naar verwachting in de westerse wereld toenemen. Deze ontwikkeling in 
ogenschouw nemend vormen de bevindingen in dit proefschrift een basis voor 
verder onderzoek en dragen zij bij tot een beter begrip van de immunohistolo-
gie van het BCC. Tevens kan dit proefschrift een bijdrage leveren aan de 
ontwikkeling van nieuwe therapeutische modaliteiten. 
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Het in dit proefschrift beschreven onderzoek werd verricht op de afdeling 
Dermatologie en Venereologie van het Academisch Ziekenhuis. Rotterdam, 
Dijkzigt. Er bestond een nauwe samenwerking met de afdeling Pathologie. 
De vele mensen die op enigerlei wijze bijgedragen hebben aan de totstand-
koming van dit proefschrift wil ik hartelijk bedanken. Enkelen wil ik spedaal 
noemen. 
Prof.dr. Th. van Joost heeft mij in de gelegenheid gesteld het wetenschappe-
lijk werk te verrichten ondanks inkrimping van de afdeling en een beperkte 
budgettering. Beste Thea, de talrijke bijeenkomsten waar werd "gebrainstormd" 
heb ik als zeer waardevol ervaren. 
Dr. B. Tank wil ik bedanken voor de grate inzet en deskundigheid bij de 
begeleiding van het onderzoek. Beste Bob, mede dankzij jouw intensieve 
coaching, bestaande uit o.a. talrijke discussies over tumor-immunologie, 
medebeoordeling van histologische preparaten, het stellen van deadlines, 
zorgvuldige kritische correcties van de manuscripten, kon het onderzoek 
resulteren in dit proefschrift. 
Prof. dr. R. Benner, prof. dr. R.O. van der Heul en prof. dr. D.]. Ruiter ben ik 
zeer erkentelijk voor het kritisch lezen van het proefschrift en het plaatsen van 
waardevolle kanttekeningen waar dat nodig was. 
Dr. Vojislav D. Vuzevski wil ik bedanken voor zijn bijdrage in de 
beoordeling van histopathologische en electronenmicroscopische preparaten. 
Oak wil ik dr. Thea van der Kwast bedanken voor zijn waardevolle bijdrage 
aan het electronenmicroscopisch werk. De staf van de afdeling Pathologie wil 
ik bedanken voor hun cooperatie in de verwerking van het tumormateriaal. 
Dr. Ben Naafs wil ik graag bedanken voor zijn medewerking aan de 
klinische studie. De stafleden en arts-assistenten van de afdeling Dermatologie 
en Venereologie ben ik dank verschuldigd voor hun medewerking in de 
afname van biopten. De cooperatieve wijze waarop drs. S.].M. Wijthoff van de 
afdeling Plastische en Recontructieve Chirurgie mij het nodige tumormateriaal 
leverde heb ik zeer op prijs gesteld. Dr. Arthur W.M. van der Kamp introdu-
ceerde mij op het laboratorium van de afdeling Celbiologie om de nodige 
ervaring op te doen met immuno-histologische technieken. Zo kon de eerste 
steen van het onderzoek worden gelegd. 
De immunohistologische kleuringen werden op nauwkeurige wijze 
uitgevoerd door Emma van Reede. Ineke Vonk en Els Buitenhuis droegen zorg 
voor topkwaliteit vriescoupes. John Breve verzorgde op uiterst secure en 
effidente wijze de immuno-electronenmicroscopische technieken. 
Johan van der Stek leverde op zorgvuldige wijze de afdrukken voor de 
illustraties. Lia van den Heuvel droeg op adequate wijze zorg voor het vele 
typewerk. 
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Tenslotte gaat mijn dank uit naar drs. Wietske Habets-Draaisrna, mijn lieve 
levensgezel. Wietske, jij zorgde voor een prettige sfeer waarin ik kon werken 
en in de laatste fase van de totstandkoming van het proefschrift was je steun 
onontbeerlijk bij het nodige typewerk en het verrichten van de bekende hand-
en spandiensten. 
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CURRICULUM VITAE 
De auteur van dit proefschrift werd op 31 maart 1953 te Heerlen geboren. 
Hij behaalde in 1972 het diploma HBS-B aan het St.Janscollege te Hoensbroek. 
In hetzelfde jaar begon hij met de studie Biologie aan de R.U. te Utrecht en in 
1976 werd het kandidaatsexamen B5* behaald. In 1977 werd met de studie 
Geneeskunde gestart aan voornoemde universiteit. 
In 1979 werd het doctoraal examen Biologie behaald met als hoofdvak 
Antropobiologie, als bijvakken Immuno-Haematologie en Biohistorie en als 
nevenvak Klinische Immunologie. In 1983 behaalde hij het artsexamen en 
begon direct hierna met de specialisatie tot dermato-venereoloog op de 
afdeling Dermatologie en Venereologie van het Academisch Ziekenhuis Dijkzigt 
Rotterdam (Hoofden: Prof. Dr. Th. van Joost en Prof.Dr. E. Stolz). Op deze 
afdeling werd in 1984 begonnen met het in dit proefschrift beschreven 
onderzoek. In 1987 vond registratie plaats als dermato-venereoloog. 
Sinds 1 mei 1988 oefent hij de dermatologische praktijk uit in Middelburg en 
Vlissingen, in associatief verband met I. Vermeiden, en is hij als staflid 
verbonden aan de Stichting Streekziekenhuis Walcheren. 
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